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Thesis statements 
Lung nodule assessment in low-dose CT lung cancer screening: 
validation of detection and volumetric measurement 
1. For indeterminate nodules detected in screening, a short term follow-up after 
initial CT could exclude a considerable number of benign lesions from further 
work-up. (This thesis) 
2. Using a combination of computed-aided detection and nodule size cut-off in 
lung cancer screening improves the sensitivity of pulmonary nodule detection, 
and significantly reduces the false positive rate. (This thesis) 
3. The NELSON nodule management regimen has very high negative predictive 
value for lung cancer in CT lung cancer screening. (This thesis) 
4. Using different software packages influences nodule management decisions, 
especially growth categorization based on consecutive examinations. (This the­
sis) 
5. Further standardization of software for nodule volumetry and volume doubling 
time assessment is needed to optimize nodule management in lung cancer CT 
screening. (This thesis) 
6. CT features of intermediate-sized nodules cannot sufficiently distinguish be­
tween malignant nodules and subsequently resolving nodules. (This thesis) 
7. Volumetric three-dimensional measurement is more accurate than two­
dimensional evaluation of pulmonary nodules. 
8. LungCARE is a very accurate software package for measuring the volume of 
solid lung nodules. 
9. As a fruit needs not only sunshine but cold nights and chilling showers to ripen 
it, so character needs not only joy but trial and difficulty to mellow it. (H. 
Black) 
10. For a researcher, imagination is more important than knowledge. 
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1.1 Lung cancer screening 
Lung cancer is a global public health problem of epidemic proportions and re­
mains the leading cause of cancer mortality [1]. Because of the fact that lung can­
cer is often diagnosed at an advanced stage, in which curation is no longer an op­
tion, the long term survival rate of lung cancer is still low. The 5-year survival rate 
for lung cancer is approximately 16% for all stages combined [2], but increases to 
60-75% when patients are diagnosed at an early stage (stage I) [3]. Therefore, a 
method for early detection in high-risk individuals could potentially reduce mor­
tality from lung cancer. In recent years, low-dose computed tomography (CT) has 
been proposed as a screening tool. A recent report from the National Lung 
Screening Trial (NLST) indicates that low-dose CT screening reduces mortality 
from lung cancer by 20%, compared to chest radiography [4]. 
The Dutch-Belgian Randomized Lung Cancer Screening Trial (Dutch acro­
nym: NELSON) was launched in 2003. The NELSON trial is a population based 
multi-centric randomized trial. The purpose is to investigate whether lung cancer 
screening by low-dose multi-detector CT in high-risk subjects will lead to a de­
crease of 10-year lung cancer mortality by at least 25% [5]. Included participants 
are aged 50-75 years and heavy (ex-)smokers. Four rounds of CT screening are 
performed; at year 1 (baseline round), 2 (the 2nd round), 4 (the 3rd round), and 
5.5 (the 4th round). The control arm receives no intervention except for advice on 
smoking cessation. 
1.2 Volume-based evaluation in lung cancer screening 
Lung nodules are frequently found in CT screening. Many nodules found in 
screening have an indeterminate size, meaning that the possibility of being lung 
cancer cannot be eliminated at first detection. Since these indeterminate lesions 
are not eligible for immediate histological evaluation, they are often re-examined 
after an interval. Nodule growth is important in the differentiation between ma­
lignancy and benignancy. Although nodule diameter is still the main discrimina­
tor in nodule categorization in lung cancer screening trials, the probability that a 
nodule will demonstrate growth on diameter alone is small [6]. Compared to di-
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ameter, change of volume has higher sensitivity and accuracy for the evaluation of 
nodule growth. 
Based on nodule volume, volume doubling time (VDT) was introduced as a 
crucial diagnostic tool in growth assessment, especially in case of sub-centimeter 
lesions [7]. The VDTs of most benign pulmonary nodules were found to be more 
than 450 days, whereas the VDTs of malignant lesions were usually less than 400 
days [7]. Of current lung cancer screening trials in Europe and North America, the 
NELSON study is the first study, in which the probability of malignancy in case of 
indeterminate-sized nodules is based on volume and VDT. This strategy of screen­
ing for lung cancer with the use of volume CT diminished the need for follow-up 
evaluation in participants with an indeterminate test result. The advantages of 
volumetric measurements become fully apparent when a volumetric comparison 
can be made with a previous indeterminate CT scan. It reduced the number of 
follow-up examinations in participants with an indeterminate test result without 
reducing the overall sensitivity of the technique. Using volumetric assessment, the 
NELSON trial generated less false positive cases, compared to the NLST trial 
based on diameter measurement [8]. That trial recently showed a positive CT in 
24.2% of participants, with 96.4% being false positive results. Nowadays, dedi­
cated software is used to assist in evaluation of pulmonary nodules, such as com­
puter-aided detection (CAD) and semi-automated volumetry. 
1.3 Computer-aided detection (CAD) system 
In lung cancer screening, small pulmonary nodules are extremely common find­
ings, but are uneasy to detect [9-10]. In screening, a radiologist has to read a large 
number of images in a short time. Fatigue increases the risk of misdiagnosis due 
to perceptual errors. Meanwhile, although the introduction of low-dose CT in 
lung cancer screening protocols was found effective in detecting peripheral lung 
cancers at an early stage [n-13], it may be more difficult for screening radiologists 
to find lesions in case of increased image noise due to low dose and thin slice 
thickness. To reduce the number of missed lesions, double reading has been rec­
ommended [14]. The utilization of double reading in the setting of lung cancer 
screening has been debated [15]. Although double reading improves nodule detec-
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tion over single reading, double reading is not widely used in clinical routine be­
cause of limited human resources and cost-effectiveness [16]. Computer-aided 
detection (CAD) of pulmonary nodules may help to address that problem by be­
ing utilized as an assistant reader [17]. 
An important application of CAD is to detect lung nodules [17]. For radiolo­
gists, various factors affect nodule recognition during screening including reader 
experience and variability, CT technique and viewing conditions, as well as nodule 
characteristics [18]. The performance of readers can be influenced by nodule loca­
tion and its relationship to surrounding anatomical structures [19-20]. For exam­
ple, in central lung regions, nodules can go undetected because they can be con­
fused with blood vessels imaged in cross sections [21-22]. A lesion not noticed by a 
reader because of a particular location, may often be detected in retrospective 
review after being detected on a follow-up scan. In the Mayo Clinic study [23], 
about one third of nodules were missed at baseline, but were later detected at fol­
low-up screening. Therefore, CAD has been introduced to assist radiologists to 
improve the efficiency to handle large data sets and the sensitivity of nodule de­
tection. 
For more than a decade, considerable effort has been focused on developing 
automated systems to detect suspicious lesions in thoracic CT images. Numerous 
studies have demonstrated that the introduction of CAD in radiological practice 
can significantly improve diagnostic accuracy of pulmonary nodule detection. Us­
ing CAD software packages, a wide range in sensitivity, from 54% to 95% has been 
reported, with 0.55 to 8.3 false positive findings per CT examination [24]. Rubin et 
al. reported that the mean sensitivity was 50% for an individual reading and 76% 
after adding CAD [25]. In another study, CAD as second opinion after single read­
ing increased the sensitivity to 79% which proved to be significantly better than 
double reading [26]. Therefore, despite the high false positive rate, CAD can be 
valuable to increase sensitivity of nodule detection. 
1.4 Semi-automated nodule volumetry 
In lung cancer screening, accurate volumetry is essential to assess nodule growth. 
It is well known that accurate and precise volume measurement depends on a 
4 
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number of factors, such as CT acquisition protocol, image reconstruction parame­
ters and nodule characteristics [27-29]. In recent years, nodule volume can be 
semi-automatically measured by using dedicated software. The software algo­
rithm generally relies on complex shape-analysis for nodule segmentation from 
adjacent structures [30-31]. It has been reported that voiumetry software from dif­
ferent vendors had substantial variations in segmentation performance which may 
cause misdiagnosis [32]. In lung cancer screening, usually multiple centers and CT 
equipments are involved [6]. Systematic differences in volume measurements be­
tween software packages could influence nodule categorization and treatment 
decisions. Thus, in a setting based on nodule volumetry, the influence of software 
packages on volume measurement and VDT evaluation needs to be investigated. 
1.5 Resolving nodules 
With the widespread of thin-slice CT and dedicated software, the number of de­
tected pulmonary nodules has increased enormously, as compared with tradi­
tional CT and X-ray radiography. Up to 66% of participants enrolled in screening 
trials have at least one small-to-medium-sized pulmonary nodule [23]. An impor­
tant topic in lung cancer screening is the interval of follow-up. The volume dou­
bling time (VDT) of most benign pulmonary nodules were found to be more than 
450 days, whereas VDTs of malignant lesions were usually less than 400 days [7]. 
Currently, in several randomised controlled trails which are underway, the inter­
val of early follow-up imaging is designed as 3-, 6-, or 12-month [33-36). 
The majority of indeterminate nodules is not malignant [5], and may repre­
sent granulomatous or infectious lesions, or enlarged lymph nodes. These benign 
nodules are often resolved completely or were reduced in size at short-term fol­
low-up either after therapy with antibiotics or spontaneously [n]. Several studies 
emphasized the importance of short-term CT follow-up for indeterminate lung 
nodules. In the study by Felix et al. [37], the mean resolving interval of 32 local­
ized ground glass opacities was 7.6 months. Libby et al. [38] from Early Lung Can­
cer Action Project (ELCAP) reported that 12% of nodules � 5mm in diameter had 
complete resolution within 2 months of the initial CT in baseline screening both 
with and without having received antibiotics. Therefore, for indeterminate nod-
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ules detected in screening, a short term follow-up after initial CT could exclude a 
great amount of benign lesions from malignancy. 
1.6 Outline thesis 
The issues of detection, volumetric measurement and characterization of pulmo­
nary nodules were investigated in this thesis. In Chapter 2, we describe the de­
tails regarding participant recruitment, CT acquisition and nodule management 
protocol in the NELSON trial. In Chapter 3, we investigate the results of low-dose 
CT lung cancer screening from the baseline and second round. Subsequently, in 
Chapter 4 and 5, we investigate the implementation of CAD software, and volu­
metry variability among different software packages. Finally, in Chapter 6, we 
retrospectively studied the nodule features associated with complete disappear­
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Abstract 
The Dutch-Belgian Randomized Lung Cancer Screening Trial (Dutch acronym: 
NELSON study) was designed to investigate whether screening for lung cancer by 
low-dose multi-detector computed tomography ( CT) in high risk subjects will 
lead to a decrease in 10-year lung cancer mortality of at least 25% compared to a 
control group without screening. Since the start of the NELSON study in 2003, 
7557 participants underwent CT screening, with scan rounds in year 1, 2, 4 and 6. 
In the current review, the design of the NELSON study including participant se­
lection and lung nodule management protocol, as well as results on validation of 




Lung cancer is the most common cause of cancer-related death in the world [1]. At 
the time of diagnosis, lung cancer is often already in an advanced stage, with 5-
year-survival of only 15% or less [2]. Observational studies in high-risk popula­
tions have shown that spiral computed tomography (CT) screening detects more 
lung cancers than chest X-ray screening (3,4], with 55-85% of CT-detected lung 
cancers being at a surgically removable stage (stage I). However, observational 
studies are prone to lead-time, length-time and over-diagnosis bias. Randomized 
studies are needed to compare disease-specific mortality between a screened and 
an unscreened population. This was the reason to launch the Dutch-Belgian Ran­
domized Lung Cancer Screening Trial (Dutch acronym: NELSON study) in Sep­
tember 2003. The hypothesis of the NELSON study is that lung cancer screening 
by low-dose spiral CT will reduce 10-year lung cancer mortality by 25% in high 
risk ( ex-)smokers between 50 and 75 years of age. 
NELSON study trial design 
Participant selection and recruitment 
During the first recruitment phase, men aged 50-75 years from 7 districts in the 
Netherlands and men and women from 14 municipalities around Leuven in Bel­
gium were sent a questionnaire about health, smoking, cancer history, and other 
lifestyle and health factors. Based on the smoking history, the estimated lung can­
cer mortality risk of the respondents was determined. Next, the required sample 
size including required participation rate was determined. Included were current 
smokers and former smokers with 10 years or less of cessation, who smoked more 
than 15 cigarettes daily for over 25 years or more than 10 cigarettes daily for over 
30 years. Exclusion criteria were a moderate or bad self-reported health, inability 
to climb 2 flights of stairs, body weight � 140 kg, lung cancer less than 5 years ago 
or still under treatment, current or past renal cancer, melanoma or breast cancer, 
and chest CT less than 1 year. The aim was to include 16,000 participants, half in 
the screen arm and half in the control arm. The trial was approved by the Dutch 
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Minister of Health and the ethics board at each participating center. All partici­
pants gave written informed consent. For more details on participant selection 
and recruitment as well as numbers concerning response rates, see van Iersel et al 
[5] .  
To conduct this logistically complex multi-centre study, the NELSON man­
agement system was developed. This is a web-based interactive database applica­
tion for data collection and management of all study related processes such as the 
selection and randomisation of participants, electronic storage of forms, study 
monitoring, reporting of scan results and scheduling of appointments for follow­
up scans. 
The remainder of this review concerns the screen arm of the study. Partici­
pants randomised to the screen arm were invited to one of the four screening sites 
(University Medical Center Groningen, University Medical Center Utrecht and 
Kennemer Gasthuis Haarlem in the Netherlands, and University Hospital Gasthu­
isberg Leuven in Belgium). Screening rounds took place in year 1, 2, 4, and 6. On 
one day, participants underwent CT (see below), and, depending on the screening 
round, blood sampling and pulmonary function testing. Pulmonary function tests 
included forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) 
with a pneumotachograph. Participants received a quality of life questionnaire 
after each visit to the screening site. 
CT scan protocol 
For chest CT scanning, 16-detector CT scanners (Mx8ooo IDT or Brilliance 16P, 
Philips Medical Systems, Cleveland, OH, USA, or Sensation-16, Siemens Medical 
Solutions, Forchheim, Germany) were used. Scans took about 12 s in spiral mode 
with 16 x 0.75 mm collimation and 15 mm table feed per rotation (pitch = 1.3). 
Scans were obtained in a cranio-caudal scan direction, without contrast media, in 
low-dose setting. Depending on the body weight ( <50, 50-80 and >80 kg) the kVp 
settings were 80-90, 120 and 140 kVp, respectively. To achieve a CTDlvoI of o.8, 1.6 
and 3.2 mGy, respectively, the mAs settings were adjusted accordingly dependent 
on the machine used. To minimise breathing artefacts, scans were performed in 
inspiration after appropriate instruction of the participants. Data acquisition and 
14 
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scanning conditions were standard across screening sites and were the same for 
all rounds of the screening [6]. Data sets were derived from images of the lung 
with a thickness of 1 mm, reconstructed at overlapping 0.7-mm intervals. Isotropic 
data sets allowed for volume measurements with good reproducibility, even in 
case of small lesions [ 7]. 
Table 1 Nodule categorization based on size and density (new nodules) and growth rate 





A benign nodule (with faVbenign calcifications) or other benign abnormalities 
A nodule, smaller than NODCAT3. not belonging to NODCAT1 
Solid Partial solid 
50 s V s  500 mm3 Solid component 50 s V s  500 mm' 
Non-solid 
NODCAT 3 dmoao .? 8 mm 
Pleural based: 5 s dm,, s 1 0 m m  Non-solid component. d,..10 1? 8 mm 
V >  500 mm' 
NODCAT 4 
Pleural based: d,.� > 1 o mm 
GROWCAT A VDT > 600 days 
GROWCAT B 400 s VDT s 600 days 
Solid component: V > 500 mm' 
GROWCAT C VDT < 400 days, or new solid component in non-solid lesion 
(non-existing 
category) 
V = volume; dm,n = minimal diameter; dmean = mean diameter; VDT = volume doubling  time. 
CT reading protocol 
Images were read on Siemens Leonardo workstations using the Syngo LungCARE 
software package (Version Somaris/5 VB 10A-W) for semi-automated volume 
measurements. Images were interpreted both at lung window and mediastinal 
settings. The first reading was performed by a reader with experience in reading 
chest CT scans varying from none to more than 20 years. In case of inappropriate 
segmentation (i.e., nodules that were attached to a fissure or to a vessel), the 
reader was allowed to enter manual measurements, which overruled the auto­
matically generated volumes. Baseline and follow-up images were reviewed and 
displayed simultaneously on one workstation. Data generated by the LungCARE 
1 5  
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software were uploaded into the NELSON Management System, which automati­
cally detected whether a nodule was new or had been present previously and 
which calculated the percentage change in volume and the volume-doubling time 
in days. Second readings were done by two radiologists with 6 years of experience. 
The 2nd readers were unaware of the conclusion of the first reader. In case of dis­
crepancy, a third reader made the final decision. More details on the method of 
evaluation of lung nodules can be found in Gietema et al [7] . 
Lung nodule definitions and management 
A nodule was further evaluated if it did not meet criteria for benign lesions. Nod­
ule volume was obtained semi-automated by LungCARE software; for certain 
nodules like pleural-based nodules, measurement of diameters from a point per­
pendicular to the costal pleura was performed manually. In addition to size, nod­
ule characteristics like shape and surface were noted. Growth was defined as 
change in volume of at least 25% between scans of subsequent scans, based on 
validation studies with repeated low-dose CT on the same day, in which the 
measurement error was maximally 25% [7,8]. The volume-doubling time was cal­
culated as described previously [6]. Growing nodules were classified into three 
growth categories according to their volume-doubling time. The definitions of the 
different categories of lung nodules are shown in Table 1. 
Based on the highest nodule category found, management was determined. 
Table 2 provides an overview of nodule management for the baseline and inci­
dence scans. NODCAT 3 was defined as an indeterminate test result which re­
quired a repeat scan 3 to 4 months later to assess growth. During incidence 
screening, the test result (negative, indeterminate, positive) was based on the 
highest GROWCAT or the highest NODCAT in case of a new nodule. For new 
nodules, the same classification according to size was made as for the baseline 
screening round. Follow-up was at shorter interval, however, because at incidence 
screen new nodules are supposed to have a relatively higher growth rate. 
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Table 2 NELSON management protocol for non-calcified pulmonary nodules in the dif­


















gist for work-up and 
diagnosis 
Negative test 
CT in year 2 
Negative test 
CT in year 2 
Positive test 
Refer to pulmonolo-




CT in year 4 
Indeterminate test 
CT after 1 year 
Indeterminate test 
CT after 6-8 weeks 
Positive test 
Refer to pulmonolo-
gist for work-up and 
diagnosis 
Negative test 
CT in year 4 
Indeterminate test 
CT after 1 year 
Positive test 
Refer to pulmonolo-
gist for work-up and 
diagnosis 
Year 4 Year 6 
Negative test Negative test 
CT in year 6 End of screening 
Indeterminate test Indeterminate test 
CT after 1 year End of screening 
Indeterminate test Indeterminate test 
CT after 6-8 weeks CT after 6-8 weeks 
Positive test Positive test 
Refer to pulmonolo- Refer to pulmonolo-
gist for work-up and gist for work-up and 
diagnosis diagnosis 
Negative test Negative test 
CT in year 6 End of screening 
Indeterminate test Indeterminate test 
CT after 1 year CT after 1 year 
Positive test Positive test 
Refer to pulmonolo- Refer to pulmonolo-
gist for work-up and gist for work-up and 
diagnosis diagnosis 
If the highest category was a NODCAT 4 of GROWCAT C, the participant 
was referred to a chest physician via the general practitioner, usually the chest 
physician associated with the screening center. Primary objective was to confirm 
the presence of malignancy by performing routine physical examinations, routine 
laboratory tests and a bronchoscopy (bronchial washing for cytology and culture, 
and transbronchial biopsy or brushing on indication) . If malignancy was proven, 
staging was performed, followed by surgical resection of the nodule. The work-up 
for participants with GROWCAT C was essentially the same as for NODCAT 4, 
except that for the former nodules a final histological diagnosis had to be ob­
tained either by FNA, video-assisted thoracoscopic surgery, or wedge resection 
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and examination on frozen section. The workup, staging, and treatment were 
standard across all screening sites and were performed according to published 
guidelines. 
CT nodule evaluation results in the NELSON study 
Since the start of the NELSON study, numerous studies on CT nodule evaluation 
in the trial have been published. The results of a number of these will be shortly 
mentioned. The studies can be separated into variability studies and studies on 
nodule characteristics suggestive of malignancy / benignancy. 
An already mentioned study [7] investigated the inter-observer variability of 
semi-automated volume measurements of small-to-intermediate size lung nod­
ules (NODCAT 2 and 3). Inter-observer correlation was very high (r = 0.99). 
Nearly 90% of nodules did not show any variation in volume with double reading. 
In only 3.7% there was a volume difference of > 10%, mostly due to incomplete 
segmentation due to irregular shape or margins. The variability of volume meas­
urements was, in a further study [9] ,  found to be related to nodule morphology, 
location and size. Volume disagreement was most likely in case of juxtavascular 
and irregular nodules. In a third study [10] , semi-automated nodule volumes were 
compared for CT data sets reconstructed with different settings of section thick­
ness and kernel. The repeatability coefficients were found to differ according to 
setting, depending also on nodule location and morphology. The volume meas­
urement was most repeatable for 1 mm section thickness with soft kernel. In case 
of serial CT studies, consistent reconstruction parameters were concluded to be 
essential. 
Valuable knowledge about characteristics of lung nodules associated with 
cancer risk was obtained in the NELSON study [11-13] . Solid nodules at intermedi­
ate size (NODCAT 3) were evaluated by CT at 3 months and at 1 year after base­
line. Cancers were found to be non-spherical and purely intra-parenchymal, with­
out attachment to vessels, the pleura, or fissures [n]. In non-smooth nodules 
without attachment, the only predictor of malignancy was size. The results sug­
gest that the risk of malignancy in smooth or attached solid nodules at intermedi-
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ate size is extremely low. In a study of the intermediate-to-large size nodules 
(NODCAT 3 and 4) [12], especially size and to a lesser extent irregular shape and 
margin were found to increase the likelihood of malignancy. Baseline CT density 
of the lung nodule was not predictive of malignancy. However, an increase in CT 
density was suggestive of malignancy [13] in intermediate size nodules (NODCAT 
3) . Furthermore, the majority of both benign and malignant nodules did not 
change of characteristics during 1 year of follow-up. 
Screening results from the NELSON study 
In 2009, the NELSON screening results from the first and second screening round 
were published in the New England Journal of Medicine [14]. The mean age of the 
population was 59 years, mean number of pack-years was 42. Of the 7557 partici­
pants who underwent CT screening, 1.6% (119) had a positive baseline scan. In ad­
dition, of the 19.2% (1451) of participants that had one or more intermediate size 
nodules (NODCAT 3) and thus an indeterminate test result, 5.3% showed a grow­
ing nodule suspected for malignancy (GROWCAT C) on the 3-month follow-up 
scan. Figure 1 is an example of a GROWCAT C nodule that was proven to be lung 
cancer. Combined, 2.6% (196) had a positive test result. Seventy were found to 
have lung cancer, with benign disease or other cancer in 107. Lung cancer detec­
tion rate was 0.9%. Sensitivity of the first screening round was 94.6%, negative 
predictive value 99.7%. There were only 3 interval cancers between the first and 
second screening round. At the second screening round, 1.8% (128) of participants 
had a positive result, with 54 turning out to have lung cancer. Sensitivity of the 
second screening round was 96.4%, with a negative predictive value of 99.9%. 
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Figure 1 Baseline and 3-month follow-up CT scan images in a 68-year old participant of 
the NELSON study. Transverse thin-section CT (a , c) and volume-rendered 
reconstruction (b, d) images show a lobulated pulmonary nodule with vessel attachment 
(boxed on a, c and green area in b, d). On the baseline scan (a, b) the volume was 303 
mm3. On the 3-month follow-up CT (c, d), the volume was 576 mm3. This is consistent 
with a percentage volume growth of 90% and a volume-doubling time of 98 days. 
Histopathology of the resected nodule: squamous cell carcinoma. 
Screening results from the NELSON study 
In 2009, the NELSON screening results from the first and second screening round 
were published in the New England Journal of Medicine [14]. The mean age of the 
population was 59 years, mean number of pack-years was 42. Of the 7557 partici-
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pants who underwent CT screening, 1.6% (119) had a positive baseline scan. In ad­
dition, of the 19.2% (1451) of participants that had one or more intermediate size 
nodules (NODCAT 3) and thus an indeterminate test result, 5.3% showed a grow­
ing nodule suspected for malignancy (GROWCAT C) on the 3-month follow-up 
scan. Figure 1 is an example of a GROWCAT C nodule that was proven to be lung 
cancer. Combined, 2.6% (196) had a positive test result. Seventy were found to 
have lung cancer, with benign disease or other cancer in 107. Lung cancer detec­
tion rate was 0.9%. Sensitivity of the first screening round was 94.6%, negative 
predictive value 99.7%. There were only 3 interval cancers between the first and 
second screening round. At the second screening round, 1.8% (128) of participants 
had a positive result, with 54 turning out to have lung cancer. Sensitivity of the 
second screening round was 96.4%, with a negative predictive value of 99.9%. 
Conclusion 
The first results of the NELSON study show the value of 3D-based lung nodule 
management for CT lung cancer screening, with an extremely high negative pre­
dictive value. The NELSON study has several features that distinguish this trial 
from f.e. the National Lung Cancer Screening trial [15]. First of all, the nodules 
detected at baseline and new nodules detected at incidence screening were classi­
fied and managed according to volume. At (annual) repeat CT scanning, the first 
assessment is whether there is growth or not, and if so, a nodule is subsequently 
classified in one of three growth categories based on VDT. NELSON is the first 
large lung cancer screening trial in which semi-automated, volumetric nodule as­
sessment is routinely applied and forms an integral part of the nodule manage­
ment protocol. Volumetric, 3D measurements have been found to be more accu­
rate than 2D evaluation of pulmonary nodules [16,17]. This was confirmed in our 
study by an extremely low rate of interval cancers. 
Another major difference is the differentiated manner with which lung nod­
ules were managed, according to size and density. Although in a screening setting, 
the sensitivity has to be very high, the specificity has to be high enough to limit 
the number of false positives. A high false positive rate leads to unnecessary anxi-
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ety, costs and morbidity. The NLST screening trial recently showed a positive CT 
in 24.2%, with 96.4% being false positive results. By adding 3 to 4 month follow­
up CT in the NELSON study for nodules of intermediate size, the number of false 
positive findings could be greatly reduced as many intermediate nodules were 
found to have resolved or have a non-malignant growth pattern. In the NELSON 
study, only 2.6% of the participants had a positive baseline screening result, with 
a false positive rate of 64.3%. 
Follow-up of the NELSON study population is ongoing. Within 3 years, the 
10-year mortality results are expected, which will provide solid evidence whether 
lung cancer screening in high risk subjects by low dose CT does decrease lung 
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The use of multidetector computed tomography ( CT) in lung-cancer screening 
trials involving subjects with an increased risk of lung cancer has highlighted the 
problem for the clinician of deciding on the best course of action when noncalci­
fied pulmonary nodules are detected by CT. 
Methods 
A total of 7557 participants underwent CT screening in years 1, 2, and 4 of a ran­
domized trial of lung-cancer screening. We used software to evaluate a noncalci­
fied nodule according to its volume or volume-doubling time. Growth was defined 
as an increase in volume of at least 25% between two scans. The first-round 
screening test was considered to be negative if the volume of a nodule was less 
than 50 mm3, if it was 50 to 500 mm3 but had not grown by the time of the 3-
month follow-up CT, or if, in the case of those that had grown, the volume­
doubling time was 400 days or more. 
Results 
In the first and second rounds of screening, 2.6% and 1.8% of the participants, re­
spectively, had a positive test result. In round one, the sensitivity of the screen 
was 94.6% (95% confidence interval [CI], 86.5 to 98.0) and the negative predictive 
value 99.9% (95% CI, 99.9 to 100.0). In the 7361 subjects with a negative screening 
result in round one, 20 lung cancers were detected after 2 years of follow-up. 
Conclusions 
Among subjects at high risk for lung cancer who were screened in three rounds of 
CT scanning and in whom noncalcified pulmonary nodules were evaluated ac­
cording to volume and volume-doubling time, the chances of finding lung cancer 1 





The use of multi-detector computed tomography (CT) has increased the chance of 
finding non-calcified pulmonary nodules [1,2], and as a result, clinicians often face 
the problem of deciding on the best course of action with respect to such nodules 
when they are found in asymptomatic subjects who have an increased risk for lung 
cancer [3]. This difficulty is especially evident in CT-based screening programs for 
lung cancer. The current practice is to refer participants in these programs for ad­
ditional diagnostic evaluation if they have a non-calcified nodule that is larger 
than s mm in diameter [4-9]. In designing the Dutch-Belgian randomized lung 
cancer screening trial (Nederlands-Leuvens Longkanker Screenings Onderzoek 
[NELSON]), we adopted a strategy that was meant to provide an inexpensive and 
simple follow-up process without increasing the false negative rate of the screen­
ing test [10]. The strategy entailed the use of the volume and volume-doubling 
time of a non-calcified nodule as the main criteria for deciding on further action. 
In this article, we report an evaluation of this strategy, which involved the tracking 
of individual nodules and the collection of 2-year follow-up data from the 
screened population of the NELSON trial. 
Methods 
Participants 
We randomly assigned eligible participants in NELSON, who were recruited as 
described previously [u], to undergo CT screening at baseline (first round), 1 year 
later (second round), and 3 years later (third round, 2 years after the second 
round), or no screening. The purpose of the trial is to determine whether at 10 
years after randomization CT screening will have reduced mortality from lung 
cancer by at least 25%. The trial was approved by the Dutch Minister of Health 





A 16-detector CT scanner (Somatom Sensation 16, Siemens Medical Solutions or, 
at the screening site in Utrecht, Mx8ooo IDT or Brilliance-16P, Philips Medical 
Systems) was used at each of the screening sites. Data sets were derived from im­
ages of the lung with a thickness of 1 mm that were reconstructed at overlapping 
0.7-mm intervals. Isotropic data sets allowed for volume measurements with good 
reproducibility, even in the case of small lesions. Data acquisition and scanning 
conditions were standard across screening sites and were the same for all rounds 
of screening [10]. At each site, CT data were analyzed on one type of digital work­
station (Leonardo, Siemens Medical Solutions) with the use of software for semi­
automated volume measurements (LungCare, version Somaris/5 VA70C-W, Sie­
mens Medical Solutions) [13,14]. In the case of inappropriate segmentation (i.e., 
nodules that were attached to a fissure or to a vessel), the radiologist was allowed 
to enter manual measurements, which overruled the automatically generated vol­
umes. Data generated by the LungCare software were uploaded into the NELSON 
Management System, which automatically detected whether a nodule was new or 
had been present previously and which calculated the percentage change in vol­
ume and the volume-doubling time in days (Supplemental Figure A). 
A nodule was classified as non-calcified if it did not meet previously speci­
fied criteria for a benign lesion [4]. For solid pleural-based and non-solid pulmo­
nary nodules, the diameter was determined manually, and the volume-doubling 
time was calculated as described previously [10] (Supplemental Figure A). In the 
case of pleural-based nodules, the diameter was measured at a point perpendicu­
lar to the costal pleura. In the case of partially solid lesions, only the volume of 
the solid region was used. The diameter was defined as the average of the maxi­
mum length and width of the nodule. Growth was defined as a change in volume 
of at least 25% between the first and second scans or between the second and 
third scans. The 25% threshold was based on three zero-change data sets in which 
the variation in volume of individual nodules was assessed between two low-dose 
CT scans. After the first of these scans, the patient returned to the examining ta­
ble for the second scan to simulate the condition of a repeat examination for the 
follow-up of a pulmonary nodule. In these studies, the volume measurement error 
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varied between 20% and 25% [12,14,15] Growing nodules were classified into three 
growth categories according to their volume-doubling time ( <400, 400 to 600, 
and >600 days). 
CT scans were independently read by first and second readers. The experi­
ence of the 13 first readers ranged from none to more than 20 years of experience 
reading thoracic CT scans (median, 6 years) ; both second readers had 6 years of 
experience. The second readers matched the nodules they had identified with 
nodules identified by the first readers according to location and size and com­
pared their results with those of the first readers. If the results were discrepant, 
the readers re-evaluated the scan to reach a consensus. If no consensus was 
reached, a third radiologist arbitrated the results. 
First-Round (Baseline) Scan 
A test was considered to be positive if on the CT scan any non-calcified nod­
ule had a solid component that was more than 500 mm3 (> 9.8 mm in diameter) 
and was considered to be indeterminate if the volume of the largest solid nodule 
or of the solid component of a partially solid nodule was 50 to 500 mm3 (4.6 to 9.8 
mm in diameter) or if the diameter of a nonsolid nodule was greater than 8 mm 
[10]. In subjects with an indeterminate result, a follow-up scan was obtained 3 
months after the baseline scan to assess the growth of the lesion. If at that time 
the lesion had a volume-doubling time of less than 400 days, the final result was 
declared to be positive; otherwise, it was considered to be negative. Subjects with 
positive screening tests were referred to a chest physician for workup and diagno­
sis. If lung cancer was diagnosed, the participant was treated for the disease and 
left the screening trial; if no lung cancer was found, the regular second-round CT 
scan was scheduled for 12 months after the baseline scan. 
Second-Round Scan 
When one or more new nodules were found on the second-round scan, the inter­
pretation (positive or negative result) was based on the size of the nodule, as it 
had been in round one; if the result was indeterminate, a follow-up scan was ob­
tained 6 weeks later [10]. In the case of nodules that had been detected previously, 
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the second-round result was based on the volume-doubling time. If there was no 
growth, or if the volume-doubling time was more than 600 days, the screen was 
classified as negative. If the volume-doubling time was less than 400 days, or if a 
new solid component had emerged in a previously nonsolid nodule, the scan was 
considered to be positive. When the volume-doubling time was 400 to 600 days, 
the test result was considered to be indeterminate and a follow-up scan was ob­
tained 1 year after the second-round scan. At that time, if the volume-doubling 
time was less than 400 days, the final result was considered to be positive; other­
wise it was considered to be negative. If both new and existing nodules were pre­
sent, the nodule with the largest volume or fastest growth determined the result. 
All participants with a negative second-round test result were invited to undergo 
the third round of screening 2 years after the second round. A cancer detected on 
screening was classified as a first-round or second-round cancer if it was diag­
nosed after a workup during the first year after a positive first-round or second­
round screen, respectively. Lung cancers that were detected during the first year 
after a negative first-round or second-round screening test were classified as in­
terval cancers. They were identified through linkage with the national pathology 
database, information from participants and general practitioners, and, in the 
case of round-one interval cancers, linkage with the National Cancer Registry. 
The workup, staging, and treatment were standard across all screening sites and 
were performed according to published guidelines [10,16,17] .  
All the authors contributed to the data collection and the decision to submit 
the manuscript for publication, and all the authors vouch for the accuracy and 
completeness of the data. 
Statistical Analysis 
The diagnostic sensitivity was defined as the ratio between the number of true 
positive results (participants who were diagnosed with lung cancer during the 
first year after a positive screening test) and the number of true positive results 
plus the number of false negative results (interval cancers detected during the 
same time period). Diagnostic sensitivity, specificity, positive predictive value, 
and negative predictive value were calculated at the participant level, and 95% 
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confidence intervals were determined with the use of SPSS software, version 15.0 
(SPSS). The standard for a negative baseline or second-round test result was 
based on the retrospective information that lung cancer was absent 2 years after 
the first round of screening and 1 year after the second round. Normally distrib­
uted data are shown as means ± SD. P values of less than 0.05 were considered to 
indicate statistical significance. 
Results 
First round 
The mean (±SD) age of the screened participants was 59 ± 6 years, and the mean 
number of pack-years smoked was 42 ± 19; a total of 16% of the participants were 
women. The first round of screening was conducted from April 2004 through De­
cember 2006 (Supplemental Figure B). Of the 7557 participants, 50.5% had a total 
of 8623 non-calcified pulmonary nodules, of which 98.0% were solid. Automated 
volumetric data were manually adjusted in the case of 6.3% of the nodules. The 
screening results were deter- mined to be negative in 5987 participants (79.2%), 
indeterminate in 1451 (19.2%), and positive in 119 (1.6%) (Figure 1). A total of 1536 
follow-up scans were obtained 100 ± 19 days, on average, after the baseline scan in 
participants with an indeterminate result. Including the outcome of these follow­
up scans, the results from round one of the screening were negative in 7361 par­
ticipants (97.4%) and positive in 196 (2.6%). 
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5987 Subjects tested negative 
(79.2%) 
HSI Subjects tested Indeterminate 
(19 2%} 
119 Subjects tested positive 
(1.6%) 
1395 Benign nodules were found 
(16.2% of the 8621 noncal­
cined nodules found in lhe 
total sample) 
2236 Nodules 50 to 500 mm3were found 
2101 Were so11d (24 �% of the 
131 Nodules >500 mm3 were found 
126 Were solid (1.5% of the 8623 
nodules found in the total 
sample} 
4861 Nodules <50 mm3 were found 
(56.4% of the 8621) 
8623 nodules found In the 
total sample} 
5 7 Were partial y sol d (0 7% of 
the 8623) 
5 Were partially sol,d (0.1 % of 
the 8623) 
78 Were nonsolid (0 9% of the 8623) 
33 Subjects had no 
fol ow up scan (2.3%) 
54 Nonca cif ed nodules 
were present (2.4% 
of the 2236 found in 
a'\ tf\ose who tested 
indeterminate) 
ll41 Subjects tesled negative 
(92.4%) 
2053 Noncalcified nodules 
were followed up 
486 Resolved (21 .7% of 
the 2236 nodules 
found in all those 
who tested indeter­
minate) 
1049 Had no growth 
(46.9% of the 2236) 
518 Had VDT a400 days 
(23.2% of the 2236) 
7361 Subjects tested negat ve 
(97.4%} 
77 Subjects tested 
pos tive (5 3%) 
129 Nonca c1fie-d 
nodules with VDT 
<-400 day§ \'Jere 
followed up (5 8% 
of the 2236 nodules 
found in all those 
who tested 1ndeter­
m1n<lile) 
196 Subjects tested positi,·e 
(2.6%) 
19 Were not referred for 
workup and diagnosis 
177 Were referred for workup 
and diagnosis 
107 Had benign d,'iea5e or 
other cancer 
20 Had lung cancer aher 2 yr 
of fol ow-up 
10 Had lung cance, at later 10unds 
Figure 1 Results of the First Round of Screening 
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Of the 196 participants with a positive scan, 177 were referred for workup; 19 
were not referred (9 because of a decision by the tumor board, 3 because of an 
administrative error, and 7 because they were already receiving treatment from 
another specialist). Lung cancer was diagnosed in 70 of the 177 participants who 
had a positive scan (39.5%) ; the diagnosis was made mainly by means of an inva­
sive procedure (85.7%). These 70 participants had 72 lung cancers, of which 46 
(63.9%) were classified as pathological stage I. In three subjects, no tissue for a 
histological diagnosis could be obtained. These subjects received high-dose radio­
therapy because the lesions were growing and were assessed as positive on a posi­
tron-emission tomographic (PET) scan. Of the remaining 107 subjects with a posi­
tive scan, 100 had benign disease and 7 had metastases from another cancer. In 
round one, the proportion of invasive procedures that revealed benign disease 
was 27.2%. 
The lung-cancer detection rate in round one was 0.9% (70 of 7557 subjects). 
There were four interval cancers, all of which were stage IV adenocarcinomas; 
three of these were new non-calcified nodules, and one, which had been seen in 
the first round, had a volume-doubling time of more than 600 days at the 3-
month follow-up. The sensitivity of round-one screening was 94.6% (95% confi­
dence interval [CI], 86.5 to 98.0), the specificity 98.3% (95% CI, 98.0 to 98.6), the 
positive predictive value 35.7% (95% CI, 29.3 to 42.7), and the negative predictive 
value 99.9% (95% CI, 99.9 to 100.0). Thus, in a subject with a positive CT screen­
ing test, the probability that the lesion would be malignant was 36%; with a nega­
tive screening test, the probability that a participant would not have lung cancer 
was 99.9%. 
Among the 736t negative CT scans in round one, 20 lung cancers were de­
tected during the 2 years of follow-up: 3 were round-one interval cancers, and 17 
were detected in the round-two screening. On the basis of this information, the 
negative predictive value was 99.7% (95% CI, 99.6 to 99.8). All 126 participants 
with a positive screening result at round one but with a negative workup returned 
to the screening program. After a mean follow-up of 785±263 days, 10 of these 126 
subjects received the diagnosis of pulmonary adenocarcinoma, which appeared to 
have originated from a suspicious nodule that was detected in round one (Sup-
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plemental Table A). 
Second Round 
In accordance with the trial's protocol, all the participants in the first round of 
screening, except those in whom lung cancer had been diagnosed, were invited to 
undergo screening in the second round, 12 which was conducted from April 2005 
through April 2008. A total of 7289 participants underwent screening 384 ± 59 
days after the round-one screening (Supplemental Figure A). In 1588 (21.8%) of 
these participants, a total of 2320 new nodules were detected, 29.2% of which had 
a volume of less than 15 mm3 or had been missed in round one. Automated volu­
metric data were manually adjusted in the case of 5.4% of the new nodules and 
1.9% of previously existing nodules. The second-round screening result was nega­
tive in 6719 participants (92.2%}, indeterminate in 480 (6.6%}, and positive in 90 
(1.2%) (Figure 2). Among participants with an indeterminate result, 276 had a fol­
low-up scan 77 ± 36 days after the second-round screening and 231 had a follow­
up scan 364 ± 36 days after the second-round screening. The follow-up scans were 
positive in 38 subjects, and when the results of these positive follow-up scans 
were added to the results of the 90 positive screening scans, there were 128 sub­
jects (1.8%) with positive second-round scans. Of these 128 participants, 1 patient 
died as a result of a metastatic colon carcinoma and n8 were referred for workup; 
54 of the n8 who were referred for workup (45.8%} received the diagnosis of lung 
cancer, mainly after undergoing an invasive procedure (88.9%}. The nine partici­
pants who were not referred for workup (four because of a decision by the tumor 
board, four because of an administrative error, and one be-cause the patient was 
already receiving treatment from another specialist) were invited to participate in 
the third round of screening 2 years later. In one of these nine, lung cancer was 
found 23 months after the first detection of the nodule in a nodule that had not 
been seen previously. Of the remaining 64 subjects with a positive scan, 62 had 
benign disease and 2 had another cancer (1 a thymoma and 1 lymphoma). 
There were two subjects with suspicious lesions from whom no tissue could 
be obtained for histological diagnosis. These subjects were treated with high-dose 
radiotherapy because the lesions were new and growing and were positive on a 
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PET scan. The 54 participants with lung cancer had 57 cancerous nodules, 42 of 
which (73.7%) were classified as pathological stage I, including 3 that were syn­
chronous double tumors. The lung-cancer detection rate was 0.5% (40 of 7289) 
during the first year after the second-round screening and o.8% (57 of 7289) for 
the entire 2-year period after the second and third rounds of screening. One stage 
IV small-cell and one stage IV large-cell interval carcinoma, both of which were 
present in nodules that had been absent at the time of the second-round screen­
ing, were diagnosed during the first year after the second-round screening. The 
sensitivity of the second-round screening was 96.4% (95% CI, 86.8 to 99.1), the 
specificity was 99.0% (95% CI, 98.7 to 99.2), the positive predictive value was 
42.2% (95% CI, 33.9 to 50.9), and the negative predictive value was 99.9% (95% CI, 
99.9 to 100.0). 
Additional Diagnostic Investigations 
The recall rates for CT scans among participants with indeterminate test results 
were 19.0% and 3.8% in rounds one and two, respectively (Supplemental Table B). 
No diagnostic PET or PET-CT scanning was performed in participants with posi­
tive test results, and fine-needle biopsy procedures were performed in less than 1% 
of the subjects. The rate of invasive diagnostic procedures was 1.2% in round one 
and o.8% in round two. 
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6719 Subjects tested negative (92.2%) 480 Subjects tested indeterminate (6.6%) 
503 New noncalcificd nodules 50 to 500 
mm1 were found 
90 Subjects tested positive (1 .2%) 
267 Benign nodules were found (1 1.5% 
of the 2320 new nodules found in the 
total sample) 
1493 New nodules <50 mm1 were fotmd 
(64 •% of the 23 20) 
473 \'foe solid (20.4% of the 2320 new 
nodules found in the total sample) 
12 Wer• p•rtially solid (0.5% of th• 
2l20) 
57 New noncalcitied nodules >500 mm3 
were found 
56 Were solid (2.4% of the 2320 new 
nodules found in the total sample) 
I W•s partially solid (0 0%) 
9048 fx1sting nonca!dfied nodules were 
found 18 Wm non,olid (0.8% of the 2320) 
163 [)listing noncalcified nodules with VDT 
400 to 600 days wert found (1 8% of 
the 9282 in the total Si1mp'.c} 
71 Fx1sting noncalcified nodules with VDT 
<400 day, were found (0.8% of the 
9282 in the total ,ampl•) 549 Were not followed up with 
scannrng (S.9% of the 9282 existing 
nodules found m the total sample) 
2432 Resolved (26 2% of the 9282) 
3638 Did not grow (39.2% of th• 9282) 
2429 Had VDT ,600 days (26.2% of 
the 9282) 
32 Subjects h11d no 
follow-up mn (6.7%) 
87 Nonc;,lcified nodules 
were present (13.1% 
of th• 666 
noncalcified nodules 
found in subjects 
who tested indeter· 
min�te) 
I 
410 Subjects tested 
neg•tive (85.4%) 
541 Nonc.lcified nodules 
were followed up 
230 Rtsolved (34.5% 
of the 666 
noncalcified nodules 
found in subjects 
who ttsted indeter­
minate) 
Ill Did not grow 
(20.0% of the 666) 
178 Had VDT >400 days 
(26.7% of the 666) 
7161 Subjects tested negative 
(98.2%) 
I Died 
JS Subjects tested 
positive (7.9%) 
38 Nonc;i.lcified nodule!!! 
were followed up 
35 Had VDT <400 
days (5.3% of 
the 666 
nonalc,foed nodules 
found in subjects 
who tested indetcr· 
minate) 
l Had VDT >400 days 
(0 5% of th• 666) 
I 
128 Subjects tested positive (1.8%) 
9 Were not referred for 
worlcup and diagnosis 
118 Were referred for workup 
and d,agnosis 
64 Had benign disea�e or 
other cancer 
J 
54 Had lune cancer 
Figure 2 Results of the Second Round of Screening. Some participants had more than 




In a population that was at an increased risk for lung cancer, our strategy of 
screening for lung cancer with the use of volume CT diminished the need for fol­
low-up evaluation in participants with an indeterminate test result. This strategy 
was especially useful during the second-round screening. It reduced the number of 
follow-up examinations in participants with a positive test result without reducing 
the overall sensitivity of the technique, as compared with that reported in the lit­
erature [4-8,18-23]. This report concerns itself only with how to deal with an ab­
normality that has been detected on a CT scan in this population; it does not ad­
dress the usefulness of screening for lung cancer with the use of CT scanning. 
The rate of interval cancers that were found in participants in our trial was 
similar to that found in participants in other trials [20]. The proportion of early 
(stage I) lung cancers detected in round one (63.9%} was similar to that found in 
other randomized trials [18,19,23], but lower than that found in nonrandomized 
trials (e.g., the proportion in the International Early Lung Cancer Action Program 
[I-ELCAP] was 86%, and the proportion in a trial performed at the Mayo Clinic 
was 75%} [6,7,20]. The lung-cancer detection rate in round one in I-ELCAP was 
higher than that in NELSON (1.3% vs. 0.9%) [7], despite similar median ages of the 
participants and a higher number of pack-years smoked by participants in NEL­
SON. The discrepancy was probably due to the fact that the proportion of women, 
who tend to have slow-growing cancers [24,25], was higher in I-ELCAP than in 
NELSON. Moreover, in I-ELCAP surgeons removed any nonsolid nodule that was 
larger than 8 mm, instead of waiting for the nodule to grow before removing it, as 
was done in NELSON. In our trial of subjects who had an increased risk of lung 
cancer, we found that the chances of finding lung cancer on a CT scan at 3 months, 
1 year, and 2 years after a negative first-round test were o, 1 in 1000, and 3 in 1000, 
respectively. 
In round one, the proportion of invasive procedures that revealed benign dis­
ease was 27.2%, which is similar to that found in other trials [5,6,19,21,22,26-30]. 
The advantages of volumetric measurements become fully apparent when a volu­
metric comparison can be made with a previous indeterminate CT scan. Because 
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there were no comparative CT scans available at round one, the first-round recall 
rate was almost as high as that in other trials (Supplemental Table B). The Lung­
Care software version that we used is not proprietary and can be used with any CT 
data set, regardless of the CT system, for evaluation of solid nodules and the solid 
component of partially solid non-calcified nodules smaller than 500 mm3• With 
manual correction, the mean relative deviation from the true lesion volume was 
only -0.3 ± 6.5% for these types of lesions [13]. 
As an absolute standard for negative test results, we used the absence of lung 
cancer after 2 years of follow-up, a period that is considered to be sufficient for 
concluding that a nodule is benign [2]. The 400-day threshold for volume­
doubling time that we used was based on current opinion that lung cancers with a 
volume-doubling time of 400 days or more are over-diagnosed cases [24,31]. A vol­
ume-doubling time of 500 days is regarded as the upper limit for lung cancer, even 
though some tumors may grow more slowly [32-34]; our upper limit was set at 600 
days. If a lower upper limit had been used, the rate of false negatives would have 
increased, but the rate of false positives would have decreased. Therefore, the 
ranges for volume-doubling time that we used are not definite and could be im­
proved. Finally, before we can make clinically directive recommendations, our 
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PVC (%) = 100 · (V2-V1)/ V2 
PVC < 25% 
No growth: 
Test negative 
VDT > 600 days: 
Test negative 
Supplemental Figure A 
PVC � 25% 
Calculate Volume 
Doubling Time (VDT) 
Classify in growth 
categories 
VDT 400- 600 days: 
Test Indeterminate 
3D: VDTv (days) = Pn 2 x li.tJllln (V2N1 )I 
2D: VDTd (days) = pn 2 x ll!Jll31n (MaxDiamXY2 / MaxDiemXY 
VDT < 400 days; 
Test positive 
V1 = volume of the nodule (mm3) at first detection on CT; V2 = volume of the nodule 
(mm3) at subsequent CT evaluation ; 3D = volume by three-dimensional volumetry soft­
ware (VDTv); 2D = volume estimate based on two-dimensional measurements (VDTd); 
MaxDiamXY1 = maximum diameter in X/Y-axis at first detection on CT; MaxDiamXY2 = 
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Eligible and 






Randomised or refusal to participate 
N= 15,822 N=428 (1 .4%) 
(52.7%) 
M' " 
Control ann Screen ann No first round scan n=358 (4.7%) 
N=7,907 N=7,915 
Symptomatic lung cancer n=S 
Death n=38 • Unavailable n=24 't' Personal reasons n=266 
First screening Missed 1 st round scan n=25 
round 
N=7,557 (95.5%) 
• No 2"' round scan before Apnl 111 2008 (n=293, 3.9%) 
't' Including 25 subjects who missed 1" round screening 
Second screening 
round Screen detected lung cancer n=69 
N=7,289 (96.5%) Death n=32 
Unavailable n=17 
Personal reasons n=123 
Scan after March 31th 2008 n=3 
Unknown n= 49 ' 
Supplemental Figure B CONSORT flowchart 
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Supplemental Table A Subjects with a positive 1 st round test result and a false nega-
tive work-up in whom lung cancer was diagnosed in the suspicious 1 st round nodule at 
later screening rounds 
1 st screening round Final lung cancer diagnosis 
>, qi 0 
O U  (.J 1i'i II) � �  II) C: iE C >, II) >, II) - Q) f;l Ol - ::, iii c5 � ltJ "iii C: - _, g  "O II) "O 0 "O 0 Q) Q) "iii Ol (.J Q) QI C: C: :::E QI E �  i-: 2: - i-: II) C: � $  -§, 8  Ol QI C: Ol Ol 0 II) 0 Cl Ol - o  Cl Ol I-
:E �  
·- Q) :i: 5.  i5 .!: E i5 (.) (.) VJ "O > > C. 
Lung cancer detected during 2nd round 
3months Partial- 50-500 <400 FBR with No malignancy 23 <400 
Adeno- T1 NOMO FU solid mm3 washing cac1noma 
2 3months Non- 50-500 <400 FBR with Inconclusive 36 <400 Adeno- T1 NOMO FU solid mm3 washing cacinoma 
3 Baseline Solid >500 mm3 NA FNA Fibrosis 27 <400 Adeno- T1 NOMO cacmoma 
4 3months Solid 50-500 <400 CT Rest of 20 <400 
Adeno- T1 NOMO FU mm3 pneumonia cac1noma 
5 3months Solid 50-500 400- FBR with No malignancy 1 1  <400 
Adeno-
T1 N 1 MO 
FU mm3 600 washing cacinoma 
6 Baseline Solid >500 mm' NA FBR with No malignancy 26 >600 Adeno- T1 N2MO washing cacinoma 
7 Baseline Solid >500 mm3 NA No NA 14 400- Adeno- T1 NOMO work-up• 600 cacinoma 
B 3months Solid 50-500 <400 FBR with No malignancy 24 <400 
Adeno- T1 NOMO FU mm3 washing cacinoma 
Lung cancer detected during 3"' round 
9 3months Non- 25 mm NA FBR with No malignancy 37 NA Adeno- T2NOMO FU solid washing cacinoma 
1 0  3months Solid >500 mm3 NA FBR with Fibrosis 32 >600 Adeno- T2NOMO FU washing cac,noma 
VDT = volume doubl ing time; FU = follow-up; FBR = flexible bronchoscopy; CT = com-
puted tomography; FNA = fine needle aspirate; NA = not applicable 
* Protocol violation. 
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Supplemental Table B Additional diagnostic evaluations in participants with an inde-
terminate or positive test result following first and second round screening of the NEL-
SON trial in comparison with the l iterature 
PluSS Cosmos Toronto NELSON [10] [21] [22,29, [28] Lss
t [26,271 
30] 
All No lung Lung All All All All No lung Lung Vanable no (%) cancer cancer no (%) no (%) no (%) no %) cancer cancer no (%) no (%) no ('4) no (%) 
Round one 7557 7487 70 3642 5203 3352 1 586 1556 30 
screening ( 100) (100) (100) (100) (100) ( 100) (100) (1001 (100) 
Clln1cal 1 81 1 1 1  70 1477 NA NA 244 217 27 evaluation (2) (2) ( 100) (41)  ( 1 5) (14) (90) 
Recall chest 1438 1419 19 821 482 628 325 305 20 
CT scan (19) (19) (27) (23) ' (9) (19) (21 )  (20) (67) 
Recall chest CT 1 1  1 1  1 2  1 4 NA NA 1 0 1 0 1 0 scans/subject 
Chest X-ray 55 27 28 NA NA NA 92 BO 12 (1 ) (0) (40) (6) (5) (40) 
PET or PET/CT 0 0 0 NA 1 60 NA NA NA NA (0) (0) (0) (3) 
MRI 5 2 3 NA NA NA NA NA NA (0) (0) (0) 
Lung (unction 1 47 78 69 NA NA NA 73 55 1 8  test (2) (1 )  (99) (5) (4) (60) 
Bronchoscopy 149 84 65 NA NA NA 29 16 1 3  (2) (1 ) (93) (2) ( 1 )  (43) 
FNA 1 3  5 B NA 4 57 46 1 8  28 (0) (0) ( 1 1 )  (0) (2) (3) (1 )  (93) 
Invasive 92 32 60 90 1 06 48 53 23 30 
procedure• (1 ) (0) (86) (3) (2) ( 1 )  (3) (2) (100) 
Round two 7289 7235 54 3423 4867 2686 1 398 1 390 
screening (1 00) (100) (100) ( 100) (100) (100) (100) (100) (100) 
Cl n cal 125 71 54 1450 NA NA NA NA NA evaluation (2) (1 )  (100) (42) 
Recall chest 275 267 8 1 386 142 NA NA NA NA CT scan (4) (4) (15) (41 )' (3) 
Recall chest CT 1 1  1 1  1 .4 1 1  NA NA NA NA NA scans/subject 
Chest X-ray 35 17  18 NA NA NA 64 NA NA 
(0) (0) (33) (4) 
PET or PET/CT 0 0 0 NA 66 NA NA NA NA (0) (0) (0) ( 1 )  
MRI 0 0 0 NA NA NA NA NA NA (0) (0) (0) 
Lung function 1 03 55 48 NA NA NA 70 NA NA test ( 1 ) ( 1 )  (89) (4) 
Bronchoscopy 98 46 46 NA NA NA 14 NA NA ( 1 )  ( 1 )  (85) ( 1 )  
FNA 3 3 0 NA NA 16  18  NA NA (0) (0) (0) ( 1 )  ( 1 )  
Invasive 61 13 48 NA NA NA NA NA NA procedure" ( 1 )  (0) (89) 
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<Ill FNA = fine needle aspirate; PET = positron emission tomography; CT = computed 
tomography; MRI = magnetic resonance imaging; NA = not available 
t Diagnostic follow-up information available for 31 6/325 and 351/360 participants with a 
positive test result at 1 st and 2nd round screen ing , respectively. 
Includes: lung biopsy or wedge resection ,  video-assisted thoracotomy, thoracotomy, 
mediastinoscopy and mediastinotomy. 
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To evaluate performance of computer-aided detection (CAD) beyond double read­
ing for pulmonary nodules on low-dose computed tomography ( CT) by nodule 
volume. 
Methods 
A total of 400 low-dose chest CT examinations were randomly selected from the 
NELSON lung cancer screening trial. CTs were evaluated by two independent 
readers and processed by CAD. A total of 1,667 findings marked by readers and/or 
CAD were evaluated by a consensus panel of expert chest radiologists. Perform­
ance was evaluated by calculating sensitivity of pulmonary nodule detection and 
number of false positives, by nodule characteristics and volume. 
Results 
According to the screening protocol, 90.9% of the findings could be excluded 
from further evaluation, 49.2% being small nodules (less than 50 mm3) .  Excluding 
small nodules reduced false-positive detections by CAD from 3.7 to 1.9 per exami­
nation. Of 151 findings that needed further evaluation, 33 (21.9%} were detected by 
CAD only, one of them being diagnosed as lung cancer the following year. The 
sensitivity of nodule detection was 78.1% for double reading and 96.7% for CAD. A 
total of 69.7% of nodules undetected by readers were attached nodules of which 
78.3% were vessel-attached. 
Conclusions 
CAD is valuable in lung cancer screening to improve sensitivity of pulmonary 
nodule detection beyond double reading, at a low false-positive rate when exclud­




The rapid development of multi-detector CT (MDCT) has increased the amount of 
data for radiologists to analyze. Reviewer's fatigue increases the risk of false­
negative diagnosis due to perceptual error. In addition, although the introduction 
of low-dose CT in lung cancer screening protocols was found effective in detecting 
peripheral lung cancers at an early stage [1-4], it may be more difficult for screen­
ing radiologists to find lesions in case of increased image noise due to low dose 
and thin slice thickness. To reduce the number of missed lesions, double reading 
has been recommended [5]. Previous studies have found that more pulmonary 
nodules are detected by double reading than by single reading [5, 6]. However, 
double reading is not widely used in clinical routine because of limited human 
resources and cost-effectiveness [7, 8]. 
Computer-aided detection (CAD) of pulmonary nodules may help address 
this problem by being utilized as an assistant reader [9-13]. A significant im­
provement in sensitivity was shown in pulmonary nodule detection, albeit at the 
disadvantage of a large increase in false-positive (FP) findings. Previous studies 
have found that CAD increases the sensitivity of pulmonary nodule detection 
compared to that of single human reading [14, 15]. In one rather small study, true­
positive (TP) findings identified with the aid of CAD complemented radiologists' 
TP findings to a greater extent than those contributed by second readers [16]. 
In lung cancer screening, small pulmonary nodules are extremely common 
findings. Previous studies using low-dose CT for early detection of asymptomatic 
lung cancer in populations at risk reported that more than 95% of nodules 10 mm 
or smaller were benign [1, 2, 17]. Avail-able data indicate that less than 1% of very 
small (less than 5 mm, corresponding to 65.4 mm3) nodules were malignant [2, 18, 
19] . Therefore, a size cut-off in CAD could be more efficient in helping radiologists 
make diagnoses. In recent years, volume instead of diameter has become an im­
portant factor to evaluate nodule size and growth. As this measure is more accu­
rate for evaluating growth [20-22] ,  a volume cut-off is likely more precise in dis­
tinguishing probably malignant and probably benign nodules. 
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The purpose of our study was to assess the performance of CAD for detection 
of pulmonary nodules as a complementary tool in a large-scale, low-dose CT lung 
cancer screening study compared to double reading, with stratification according 
to nodule volume. Double reading is the original design of nodule evaluation in 
our lung cancer screening trial. The hypothesis of the current study was that CAD 
increases sensitivity of lung nodule detection beyond double reading. 
Materials and methods 
Study population 
The subjects in this study were participants of the four screening sites of the 
Dutch-Belgian randomized trial for lung cancer screening (NELSON) by low-dose 
MDCT. The protocol required participants to be current or former smokers with a 
smoking history of more than 15 cigarettes / day for longer than 25 years or more 
than 10 cigarettes / day for longer than 30 years. The NELSON study was approved 
by the medical ethics committees of all institutions and all participants provided 
written informed consent [23] that also covered the current analysis. As a side­
study of the NELSON project, we randomly selected 400 out of 4,280 base-line 
CTs from 2005 using a statistical program (SPSS 16.0 for Windows, SPSS, Inc., 
Chicago, IL, USA). 
CT protocol 
At all screening sites 16-detector CT was used (3 Sensation-16, Siemens Medical 
Solutions, Forchheim, Germany and 1 Mx8ooo IDT or Brilliance 16P, Philips Medi­
cal Systems, Cleveland, OH, USA). CT of the entire chest was per-formed, in 
caudo-cranial direction. CT data were acquired with 16 x 0.75 mm collimation and 
pitch of 1.3. No intravenous contrast medium was used. Low-dose settings were 
applied depending on body weight (less than 50 kg, 50-80 kg and greater than 80 
kg), with corresponding kVp settings of 80-90, 120 and 140 kVp, to achieve a CT 
dose index volume of approximately o.8, 1.6 and 3.2 mGy, respectively. The mAs 
settings were adjusted accordingly depending on the machine used. To minimize 
breathing artifacts, CT data acquisition was performed at suspended maximal in-
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spiration after appropriate instructions were given to the subjects. Data were re­
constructed at 1.0-mm slice thickness, with 0.7-mm reconstruction increments 
and soft kernel (Siemens B30 filter, Siemens Medical Solutions, Forchheim, Ger­
many). The Siemens B30 kernel is the standard soft tissue reconstruction kernel. 
Transversal, 6-mm-thick maximum intensity projections (MIP) reconstructions 
were used to identify pulmonary nodules. 
Evaluation of CT examinations by double reading 
At the time of acquisition (2005), all CT images of the lungs from each examina­
tion were independently read by first and second readers (double reading) as part 
of the NELSON protocol [ 6, 23]. The first reading was performed by 13 readers 
(experience in reading thoracic CT varying from o to 20 years); the second reading 
was performed by two readers, each with 6 years of experience. Upon identifying a 
finding as a pulmonary nodule, volume measurement was performed by the indi­
vidual readers as part of the double reading. The LungCARE© software package 
(Leonardo© workstation, Somaris/ 5 VB10A, Siemens Medical Solutions, Erlangen, 
Germany) designed to aid readers in measuring and characterizing pulmonary 
nodules was used in addition to visual readings by all readers. Nodule diameter 
and volume were automatically calculated using this three-dimensional (3D) 
volumetric assessment tool. In case of inappropriate segmentation, the radiolo­
gists could perform manual two-dimensional (2D) measurements using a calliper. 
Lung CAD algorithm 
The lung CAD algorithm evaluated in this study was a commercial software ver­
sion available since 2006 (LungCAD VB10A, Siemens AG Healthcare) [24]. This is 
an extensively validated CAD software, designed as a multi-step approach aiming 
to detect parenchymal lesions at high sensitivity and specificity, focusing on solid 
lesions larger than 3 mm. All CT images were processed by this LungCAD software 
package to mark potential lesions. The findings were reviewed both as 2D-axial 
images and 3D rendered views obtained with LungCARE. The MIP reconstruction 
settings used in LungCAD were equal to those in LungCARE. 
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Evaluation of findings by consensus panel 
Retrospectively, a consensus panel of two expert radiologists with at least 8 years 
of experience in reading thoracic CT reviewed the CAD-marked images and the 
results obtained from double reading were entered into the NELSON manage­
ment system, and compared the findings in LungCARE [23]. The consensus panel 
did not search for potential additional nodules. This reference standard was simi­
lar to previously reported practices [14, 25]. The consensus panel labeled the find­
ings as "nodule" according to the definitions in the NELSON protocol [23] . Upon 
identifying a finding as a pulmonary lesion, volume measurement was performed 
by the consensus panel. Conforming with the image reading protocol used by the 
readers in the double reading, nodules smaller than 15 mm3 were not assessed 
whereas larger non-calcified solid nodules were classified into three categories 
based on size (negative nodule, smaller than 50 mm3 ; indeterminate nodule, 50-
500 mm3; positive nodule, larger than 500 mm3) [26]. A cut-off of 50 mm3 (4.6 mm 
diameter) was chosen as previous studies have shown that the possibility of ma­
lignancy in these small nodules is negligible [18, 19] . Because consistent volume 
measurement was not possible in non-/part-solid nodules, the calliper was used to 
measure the largest axial diameter of these lesions. Non-solid and part-solid nod­
ules with non-solid component at least 8 mm as well as part-solid nodules with 
solid part larger than 50 mm3 were considered indeterminate nodules. 
Findings were divided into two groups based on NELSON's nodule categories: 
findings that could be excluded from further evaluation and those that needed 
further evaluation. Findings excluded from further evaluation were subdivided 
into three sub-groups: negative nodule (smaller than 50 mm3) ,  benign lesion or 
non-lesion. Calcifications and abnormal findings not presenting as nodule shapes, 
e.g. pleural plaque, fissure thickening or fibrosis, were recorded as benign lesions. 
A finding was assigned as "non-lesion" if the finding was due to normal anatomy 
or artifact. Findings needing further evaluation consisted of indeterminate and 
positive nodules. These findings were subsequently characterized by the consen­
sus panel in terms of location (peripheral or non-peripheral), consistency (solid or 
non-/part-solid), attachment (intraparenchymal, fissure-attached, vessel-attached 
or pleural-based), shape (spherical or non-spherical) and edge (smooth or non-
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smooth) [23, 27]. Nodules were classified as peripheral if the distance to the tho­
racic wall was less than one third of the total distance from the thoracic wall to 
the lung hilum, and as non-peripheral otherwise. 
4280 NS..SON baseine CT examinations I Evaluated by double reading 
! 
400 CT examinations randomly selected 
Processed by CAD 
1667 findmr reviewed by consensus panel· 31 1 (18. %) found by double reading and CA.D 
24 � .4%) only found b� double reading 1332 9.9%) only found y CAD 
�. 
151 findmf needed further evaluation: 1 1 3  (74. %) found by double reading and CAD 
1516 findings could be excluded from further evaluation. 
198 (13. 1 %) found by double reading and CAD 
5 (3.3%) only found bi double reading 33 (21 .9%) only found y CAD 
19 (1. 2%) only found by double reading 
1299 (85.7%) only found by CAD 
7 46 (49.2%) findings could be excluded from - further evaluation, based on small size (<50 mm") of lung nodules: 
1 74 (23.3%) found by double reading and CAD 
6 w.8%) only found by double reading 566 5.9%) only found by CAD 
570 (37.6%! benign lesions: 24 (4.2% found by double reading and CAD 
13 (2.3%) only found bi double reading 533 (93.5%) only found y CAD 
� 
239 (41 .9%) benign calc1fi::ation 
148 (25.9%) pleural plaque 
87 (15.3%) fissure thickering 
34 (6%) lymph node attach to vessel 
32 (5.6%) fibrosis 
30 (5.3%) others 
200 (13.2%) non-lesions only found by CAD: 
140 (70%) vessel 
50 (25%) nb bulging 
10 (5%) otheis 




Findings from double reading and from CAD were labelled either as TP, if they 
were determined by the consensus panel as findings needing further evaluation, 
or otherwise as FP. Sensitivity for pulmonary nodules from double reading and of 
CAD findings was calculated using the consensus panel as the reference standard. 
The FP rate presented with respect to nodule volume (less than or at least 50 mm3) 
was computed as the number of FP detections per CT. Additionally, the positive 
predictive value of findings detected by CAD was calculated. The probability of 
detecting pulmonary nodules according to nodule characteristics was tested be­
tween CAD and double reading by the McNemar test. All statistical analyses were 
performed using SPSS 16.0. 
Results 
The mean age of the 400 participants was 59 ± 6 years (range 51 to 76 years). On 
332 of the 400 baseline CT examinations at least one finding was reported (Figure 
1) . A total of 1,667 findings were detected by the readers and CAD system. A total 
of 90.9 % (n = 1,516) of the identified findings could be excluded from further 
evaluation (Figure 1) . In this study, these findings were considered as FP findings. 
The FP rate was 3.7 per CT for CAD and 0.5 per CT for readers (Table 1). Excluding 
small nodules (less than 50 mm3) and regarding benign lesions and non-lesions as 
FP findings only, the FP rate for CAD decreased to 1.9. By using 50 mm3 as the cut­
off below which pulmonary nodules were disregarded, the positive predictive 
value of CAD increased from 8.9 to 16.2%. The positive predictive value of double 
reading was 35.2% and 76.1% for all nodules and nodules larger than 50 mm3, re­
spectively. 
According to the consensus panel, 151 (9.1 %) of 1,667 findings needed further 
evaluation. Of these 151 nodules, 113 were found both by readers and CAD, and 33 
and 5 were found only by CAD or readers, respectively (Figure 1). The overall sen· 
sitivity for potentially significant pulmonary nodules (indeterminate and positive 
pulmonary nodules) was 78.1% for readers and 96.7% for CAD (Table 1). 
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Table 1 Sensitivity, false positive (FP) rate and positive predictive value (PPV) of nodule 
detection for double reading and CAD in all nodules and nodules larger than 50 mm3 
All nodules Nodules > 50 mm3 
Double reading CAD Double reading CAD 
Sensitivity, % 78. 1 96.7 78. 1 96.7 
FP/examination, n 0.5 3.7 0 . 1  1 .9 
PPV, % 35.2 8.9 76. 1  1 6.2 
CAD = computer-aided detection; FP = false positive; PPV = positive predictive value 
Table 2 presents an overview of the nodules found by readers or by CAD. 
Among the 151 indeterminate and positive pulmonary nodules, 76.6% were located 
peripherally, 96.7% were solid nodules, 49.7% were intraparenchymal and 76.2% 
were spherical and 87.4% were smooth. The median volume of 146 solid nodules 
was 85.4 mm3 (range 50.0 to 1,672.4 mm3) .  Consistent volume measurement was 
not possible in the 5 non-/part-solid nodules. CAD was better in detecting most 
types of nodules, namely peripheral and non-peripheral nodules, solid nodules, 
intraparenchymal nodules, and spherical and non-spherical nodules. Some differ­
ences could not be tested for significance as some cells were empty (for non-/part­
solid, vessel-attached, non-smooth and positive nodules) . 
Only 37.9% (11/29} of vessel-attached nodules were detected by readers. A to­
tal of 69.7% of 33 nodules not detected by readers were attached nodules, and 
78.3% of these were vessel-attached (Figure 2}. Of the non-peripheral, vessel­
attached nodules, 7 out of 11 were missed by readers but all were detected by CAD. 
Of 33 nodules missed by readers at baseline, 24 were detected at 3-month or 1-year 
follow-up CT examinations. Lung cancer was diagnosed in one solid intraparen­
chymal nodule, found to have grown at the second-year screening CT. The base­
line volume of this missed nodule was 160.7 mm3• 
One fissure-attached and two pleural-based nodules were missed by CAD. 
Two of five nodules missed by CAD were non-/part-solid. A solid pleural-based 
nodule with volume 217.8 mm3 missed by CAD was diagnosed as lung cancer after 
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it was found to be growing on the 3-month follow-up CT examination, with vol­
ume doubling time less than 400 days (Figure 3). 
Table 2 Characteristics of 1 51 pulmonary nodules needing further evaluation, found by 
CAD and/or double reading 
Nodules found by 
Variable n P value 
CAD (%) Double reading (%) 
Location 
Peripheral 1 1 6 1 1 2 (96.6) 94 (81 .0) <0.01 
Non-peripheral 35 34 (97. 1 ) 24 (68.6) <0.01 
Consistency 
Solid 1 46 143 (97.9) 1 13 (77.4) <0.001 
Non-/part-solid 5 3 (60.0) 5 (1 00) NA 
Attachment 
lntraparenchymal 75 73 (97.3) 65 (86.7) <0.05 
Fissure-attached 1 8  1 7  (94.4) 1 7  (94.4) NS 
Vessel-attached 29 29 ( 1 00) 1 1  (37.9) NA 
Pleural-based 29 27 (93. 1 )  2 5  (86.2) NS 
Shape 
Spherical 1 1 5  1 1 1  (96.5) 92 (80.0) <0.001 
Non-spherical 36 35 (93. 1 )  2 6  (72.2) <0.05 
Edge 
Smooth 1 32 1 30 (98.5) 99 (75.0) <0 .001 
Non-smooth 1 9  1 6  (84.2) 1 9 ( 1 00) NA 
Volume* 
50-500 mm3 141  1 38 (97.9) 1 08 (76.6) <0.001 
>500 mm3 5 5 (1 00) 5 (100) NA 
• For 5 non-/part-sol id nodules, volume was not avai lable. 






Figure 2 Examples of pulmonary nodules needing further evaluation that were missed 
by double reading. Vessel-attached nodule with baseline volume of 161 .9 mm3 (a), in­
traparenchymal nodule with volume of 75.9 mm3 (b) . 
Through the fourth screening round (the 7th year), in total 7 lung cancers (all 
adenocarcinomas) have been diagnosed. None of the lung cancers originated from 
FP results from CAD. Three of the cancers were proven by biopsy during the base­
line round, 3 during the second screening round, and 1 at the fourth round screen-
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ing. None of the benign-appearing pulmonary nodules presented with malignant 
behavior during subsequent screening rounds. 
Discussion 
Of the 1,667 findings on lung cancer screening CT by readers and CAD, presented 
to the consensus panel, 90.9% could be excluded from further evaluation with 
small size of pulmonary nodules being the main reason (49.2%). The false-positive 
findings by CAD decreased from 3.7 to 1.9 per CT by using a nodule volume cut-off 
(larger than 50 mm3) .  Given the 151 (9.1%) findings that needed further evaluation, 
33 nodules (21.9%) would have been missed if CAD was not applied. The sensitiv­
ity of nodule detection by readers could have increased by 18.6% (from 78.1% to 
96.7%) if CAD had also been used. However, only one lung cancer missed by 
readers was detected by CAD. 
Numerous studies have demonstrated that the introduction of CAD in radio­
logical practice can significantly improve the diagnostic accuracy of pulmonary 
nodule detection. The reported sensitivity of CAD ranged from 38 to 100% [28-35]. 
Our study indicates a high sensitivity of greater than 95% when LungCAD soft­
ware is used. By using CAD, an extra 18.6% of nodules were detected. A general 
comparison between our study and previous studies is, however, not possible due 
to the differences in methods, e.g. regarding the CT technique and the threshold 
of nodule size for CAD. These types of differences may explain the wide range in 
sensitivity reported. 
High FP rate is still a considerable drawback of CAD. In this study, the FP 
rate of CAD was low compared to that of other studies (range 1.3 to 13.4/case, av­
erage 4.7/ case) [28-35]. However, it is still higher than the FP rate for double read­
ing (0.5/case). Over 80% of the FPs in this study was reported only by CAD, of 
which nearly half could be excluded from further evaluation if nodule size was 
considered. Using a nodule volume cut-off of greater than 50 mm3, the FP rate 
decreased to 1.9 per CT. The use of 50 mm3 (equal to 4.6 mm diameter for a 
spherical nodule) as cut-off volume for pulmonary nodules is supported by the 
NELSON results [14]. As published in the New England Journal of Medicine [14], 
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the NELSON nodule evaluation protocol with a negative screening result in case 
of nodules smaller than 50 mm3 had a sensitivity for lung cancer of 94.6%, 
whereas none of the scarce interval cancers between the first and second year 
screening were due to malignancy in pulmonary nodules smaller than 50 mm3• 
The chance of finding lung cancer in a participant on a second-round screening 
CT after a negative baseline test was only 1 in 1,000, confirming the safety of the 
current approach and the negligible 1-year risk of lung cancer in very small pul­
monary nodules (smaller than 50 mm3) .  Use of CAD led to one additional lung 
cancer being detected, whereas one malignant pulmonary nodule was missed by 
CAD. Both nodules had a volume greater than 50 mm3• 
Among all FP findings identified by CAD, nearly 40% were considered be­
nign lesions by the consensus panel, e.g. fissure thickening and pleural plaque. In 
a previous study by Wormanns et al. [35] concerning nodules adjacent to the 
pleural surface, none of the 21 pleural-based findings detected by CAD were re­
garded as true pulmonary nodules. Given the high rate of this type of CAD finding 
in our study, one may conclude that CAD has difficulty in distinguishing pleura­
based nodules and pleural plaques. This may be caused by the image segmenta­
tion component of the algorithm which may regard a part of the chest wall as a 
nodule and include it in further image processing. On the other hand, the one 
lung cancer missed by CAD was a pleural-based nodule. A considerable number of 
FP findings for CAD concerned vessels and rib bulging which were frequently mis­
interpreted owing to their nodule-like appearance in cross sections. Another prin­
cipal problem was the difficulty in establishing a density value as threshold for 
lesion detection as a result of partial volume effects and motion artifacts. All non­
lesions were easily distinguished from nodules by the readers, particularly when 
3D visualization was used in the pulmonary nodule evaluation platform. 
Various factors affect nodule recognition during screening including reader 
experience and variability, CT technique and viewing conditions, as well as nodule 
characteristics [36]. The performance of readers can be influenced by nodule loca­
tion and its relationship to surrounding anatomical structures [37, 38]. The radi­
ologist has little difficulty in finding peripheral and subpleural nodules even if 
they are small because there are no vessels of similar size near the pleural surface 
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[39]. In central lung regions, however, nodules can go undetected because they 
can be confused with blood vessels imaged in axial cross sections [35, 40]. A lesion 
not noticed by a reader because of a particular location, may often be detected in 
retrospective review after being detected on a subsequent CT. We found that ves­
sel-attached nodules in particular can be missed by human readers. Although 
Marten et al. [41] reported that readers recognized more of the nodules with vas­
cular attachment, Naidich et al. [37] showed that nodules either over-lapping or 
superimposing blood vessels were harder for radiologists to identify (sensitivity 
32.5%). In our study, 30.3% of the attached nodules were not detected by human 
readers, and 78.3% of these missed nodules were vessel-attached. Furthermore, 
the mean size of vessel-attached nodules missed by readers was larger than that of 
other subtypes (data not shown).  This indicates that contact with vessels in­
creases the difficulty of detection by radiologists. The study by Naidich [37] dem­
onstrated a significant relationship between nodule location and detectability by 
human reader sensitivity: peripheral 73.9%, central 48.6%, perihilar 36.7%). Of the 
non-peripheral nodules, two-thirds were found by double reading, considerably 
higher than in the aforementioned article. However, of the non-peripheral, vessel­
attached nodules, 7 out of n were missed by readers. CAD was significantly more 
sensitive for these types of nodules detecting all n of them. In our study, the per­
centage of sub-solid nodules was low (5 nodules, 3.3%), similar to the relatively 
low prevalence in our entire lung cancer screening study (2%) [26]. Two of the 
five non-/part-solid nodules were missed by CAD but none were missed by read­
ers. Most CAD systems so far are designed and optimized for solid nodules. The 
obstacle of adequate detection of sub-solid nodules is primarily caused by the set­
ting of an attenuation range. The selection of texture features will affect the diag­
nostic performance of the final CAD scheme [42]. In a small study by Armato [40], 
four of six lung cancers not detected by automated detection were non-solid and 
two were part-solid. A computerized scheme based on the application of artificial 
neural networks to selected texture features and Gaussian curve fitting features 
may hold promise for facilitating detection of localized sub-solid nodules in CT 
[42]. The CAD used in our study does not support the detection of nodules with 
non-solid components. Furthermore, the number of sub-solid nodules was small. 
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Evaluation of the benefit of new CAD systems with improved sensitivity for sub­
solid nodules should be conducted in future studies with larger numbers of sub­
solid nodules. 
A limitation of our study is that nodule diagnosis was in most cases (inter­
mediate-sized nodules) not directly proven by biopsy but by evaluation of nodule 
growth on a short-term follow-up CT examination. However, the aim of the cur­
rent study was to assess the performance of CAD versus double reading by human 
readers for detecting potentially relevant pulmonary nodules, which is the first 
step on the road to diagnosing early stages of lung cancer. The reference standard 
for defining the presence of a pulmonary nodule was an experienced consensus 
panel. Reader experience and variability could have affected the results. However, 
by using the interpretation of the sum of all findings by a consensus panel as the 
reference standard the effect of reader variability was reduced if not minimized. 
Also, the consensus panel did not perform a free search for potential additional 
findings. It is theoretically possible that the consensus panel could have found 
one or more additional pulmonary nodules. However, in view of the extremely 
high sensitivity of CAD for pulmonary nodules [32, 34], this was considered 
unlikely. As a result of the small numbers of certain nodule types, logistic regres­
sion could not be reliably performed for all nodule characteristics. Although we 
have demonstrated the benefits of CAD complementary to double reading com­
pared to double reading alone, timing of the two modes still can be investigated; 
this actually depends on the efficiency of the workflow for CAD mark review. 
Lastly, the current analysis was based on a certain type of CAD software and a 
specific protocol for double reading and nodule evaluation. Whether the results 
can be generalized to other types of CAD software was not deter-mined; however, 
the results are in line with previous reports on the improved sensitivity of pulmo­
nary nodule detection by CAD compared to that of human readers [15, 32]. 
In conclusion, using a combination of CAD and nodule size cut-off in lung 
cancer screening improves the sensitivity of pulmonary nodule detection com­
pared to that of double reading, without missing lung cancers. Adding a nodule 
volume cut-off of 50 mm3 to CAD leads to nearly half the FP rate (1.9 versus 3.7 
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To compare volumetric measurements of solid pulmonary nodules on baseline 
and follow-up CT scans as well as the volume doubling time (VDT) for three soft­
ware packages. 
Materials and Methods 
From a Lung Cancer Screening study (NELSON}, 50 participants were randomly 
selected from the baseline round. The study population comprised participants 
with at least one pulmonary nodule at the baseline and consecutive CT examina­
tion. The volume of each nodule was determined for both time points using three 
semi-automated software packages (P1, P2 and P3). Manual modification was per­
formed when automated assessment was visually inaccurate. VDT was calculated 
to evaluate nodule growth. Volume, VDT and nodule management were com­
pared for the three software packages, using P1 as the reference standard. 
Results 
In 25 participants, 147 nodules were present on both examinations (volume: 12.0 to 
436.6 mm3). Initial segmentation at baseline was evaluated to be satisfactory in 
93.9% of nodules for P1, 84-4% for P2, and 88.4% for P3. Significant difference was 
found in measured volume between P1 and the other two packages (p < 0.001). P2 
overestimated the volume by 38 ± 24%, and P3 by 50 ± 22%. At baseline, there was 
consensus on nodule size categorization in 80% for P1&P2 and 74% for P1&P3. At 
follow-up, consensus on VDT categorization was present in 47% for P1&P2 and 
44 % for P1&P3. 
Conclusion 
Software packages for lung nodule evaluation yield significant differences in 
volumetric measurements and VDT. This variation affects the classification of 




Early diagnosis of lung cancer in a treatable stage is the main purpose of lung can­
cer screening by computed tomography (CT). Besides morphological characteris­
tics of a lung nodule, nodule size is an important factor for predicting the risk of 
malignancy. In ongoing low-dose CT lung cancer screening studies in high-risk 
populations, the prevalence of cancer varied between 0.1-1% for nodules less than 
5 mm, 1-30% for nodules measuring 5-10 mm, and 30-80% for nodules over 10 mm 
[1]. Many indeterminate lesions (5-10 mm diameter, or 50-500 mm3) detected in 
low dose CT are not suitable for immediate evaluation by positron emission to­
mography, contrast-enhanced CT, or percutaneous needle biopsy. Thus, they are 
often re-scanned after an interval to assess growth. 
Based on nodule volume, volume doubling time (VDT) was introduced as a 
crucial diagnostic tool to differentiate between malignant and benign nodules, 
especially in case of subcentimeter lesions [2]. The VDT of most benign pulmo­
nary nodules was found to be more than 450 days, whereas VDT of malignant le­
sions was usually less than 400 days [3]. Furthermore, the prognosis of lung can­
cer correlates well with the tumor growth rate [314]. Therefore, in lung cancer 
screening trials, nodule volumetry is increasingly used for follow-up of indetermi­
nate nodules in order to detect growth and thus, identify lesions with an in­
creased risk of malignancy [5]. 
Accurate three-dimensional (3D) size and growth measurements are essen­
tial in the assessment of those indeterminate nodules. Variability in volumetric 
results may cause false-positive or false-negative diagnosis. Nowadays, nodule 
volumes can be calculated by using semi-automated volumetric software. First, 
automated techniques are used to make two-dimensional (2D) measurements on 
a single CT section. This method is followed by the 3D estimation of nodule vol­
ume and growth. However, substantial variations in segmentation performance 
are reported between current lung nodule software packages [6]. Systematic dif­
ferences in volume measurements between packages could influence nodule cate­
gorization and treatment decisions. Therefore, high accuracy of segmentation is a 
requisite in software volumetric evaluation. 
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The purpose of this study is to assess the influence of lung nodule volumetric 
software packages on volume measurement at baseline and on change in volume 
over time. Additionally the impact of the software results is investigated on sub­
sequent decisions concerning nodule management. 
Materials and Methods 
Study population 
The subjects of this study were participants of the Dutch-Belgian random­
ised trial for lung cancer screening (NELSON) who underwent baseline screening 
for lung cancer by low-dose multi-detector CT [7]. The mean (±SD) age of the 
screened participants was 59 ± 6 years, and the mean number of pack-years 
smoked was 42 ± 19 [5] . The NELSON study was approved by the Medical Ethical 
Committees of all participating institutions and all subjects provided their written 
informed consent [7] that also covered the current analysis. 
In this study, 50 participants with at least one consecutive scan were ran­
domly selected from the baseline round of the NELSON study. 
CT scanning protocol 
The four participating screening sites all used 16-detector CT scanners (3 Sensa­
tion-16, Siemens Medical Solutions, Forchheim, Germany and 1 Mx8ooo IDT or 
Brilliance 16P, Philips Medical Systems, Cleveland, OH, USA). Scanning of the en­
tire chest was performed in caudal-cranial direction. Scan data were obtained in 
spiral mode, with 16 x 0.75 mm collimation and pitch of 1.3. No contrast medium 
was administered. Low-dose settings were applied depending on body weight ( < 
50 kg, 50-80 kg and > 80 kg), with kVp settings of 80-90, 120 and 140 kVp, respec­
tively, to achieve a Computed Tomography Dose Index Volume of approximately 
o.8 mGy, 1.6 mGy and 3.2 mGy. The mAs settings were adjusted accordingly, de­
pending on the acquisition system used. To minimize breathing artefacts, scans 
were performed at suspended maximal inspiration after appropriate instruction of 
the subjects. Data were reconstructed at 1.0 mm slice thickness, with 0.7 mm re­
construction increment and soft kernel (Siemens B30 filter). The Siemens B30 
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kernel is the standard soft tissue reconstruction kernel. Repeat scans were per­
formed with the same technical parameters as used for the baseline scans in low­
dose setting. 
Nodule measurement 
Due to the fact that current software packages do not support volume measure­
ment of nodules with non-solid components, only solid nodules were included in 
this study. All nodule measurements were performed once by a radiologist with 
experience in reading thoracic CT scans for over 10 years. In a previous investiga­
tion we have shown that volume disagreement in case of repeated measurements, 
using semi-automated software, is negligible for smooth and spherical nodules 
(which constituted 95% of the detected nodules) [8]. Thus, we did not repeat 
measurement of the nodule volumes. 
Nodule volumes were measured by using three different semi-automated 
software packages: Syngo LungCARE (Somaris / 5VB 10A, Siemens, Forchheim, 
Germany), OncoTREAT (vi.6, MEVIS, Bremen, Germany) and Vitrea (V2.1, Vital 
images, Minneapolis, MN, USA). P1 was assigned to the LungCARE software pack­
age, which is used for nodule evaluation in the NELSON study. Recent results 
from a phantom study indicate that the differences between the measured results 
obtained by LungCARE software and the actual volumes are very small (on aver­
age -4.9%) (9). We therefore chose to use P1 as reference for comparison. This 
choice is made for easy comparison of the other software packages and does not 
imply that one of the software packages performs better than the other since the 
actual volume of the nodules in screened subjects is unknown. The results from 
the other two packages were compared to P1. For the purpose of anonymization, 
the characters P2 and P3 were randomly assigned to the other two packages. 
In all algorithms, initial segmentation was started by clicking in the center of 
a nodule. After a fully automated evaluation, the software produced a visual 30 
presentation of the detected nodule highlighting the voxels of the nodule for 
which the initial volume was calculated. The segmented region was displayed by a 




Figure 1 Example of initial segmentation of a lung nodule in 2 screening participants. 
Low-dose, n on-contrast medium enhanced CT of the thorax. Display as maximum­
intensity projection (MIP) transverse section (upper images), and as volume rendered 
image ( lower images}, both within software package P1 . Satisfactory initial segmentation 
(a) . Unsatisfactory initial segmentation (b). 
The segmentation was judged visually by the radiologist for accuracy and 
qualitatively categorized as satisfactory or unsatisfactory based on the perceived 
reliability of volume measurement [5]. Segmentation was assigned satisfactory if 
the segmented region matched the nodule well and included no surrounding 
structures such as vessels and pleura, or if the mismatched region between the 
segmented region and nodule was visually evaluated not to exceed 20% in volume; 
otherwise, it was considered unsatisfactory (Figure 1). 
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For unsatisfactory segmentations, all packages offered the possibility to 
modify the initial segmentations manually. Modified volume instead of initial vol­
ume was regarded as final measuring volume when manual modification was per­
formed, assuming that the modified segmentation was more correct than the ini­
tial segmentation. 
All nodules were measured on baseline and follow-up scans. A comparison of 
nodule volume was made between two time points. VDT based on change in cal­
culated volumes over time was determined according the formula 1: 
VDT(days) = 
[ln 2 x .1t] (1) 
[1n(v1 -H0 )] 
(M: the days of interval between baseline and follow up scans) 
In our study, the VDTs were calculated based on nodule final measuring volumes. 
Nodule categorization and characteristics 
According to the NELSON protocol, solid nodules were classified into 3 categories 
based on their volumes at baseline (negative: < 50 mm3, indeterminate: 50-500 
mm3, or positive: > 500 mm3) and 3 categories based on their VDT at follow-up 
(GROWCAT A: > 600 days, GROWCAT B: 400-600 days, or GROWCAT C: < 400 
days) [7]. 
Additionally, nodules were classified into four subgroups based on their lo­
cation (peripheral or non-peripheral) , attachment (intraparenchyrnal, fissure­
attached, vessel-attached or pleural-based) , shape (spherical or non-spherical), 
and edge (smooth or non-smooth) [7,10]. Nodules were classified as peripheral 
when the distance to the thoracic wall was less than one third of the total distance 
to the lung hilum, and non-peripheral otherwise. A nodule was defined as in­
traparenchymal when a nodule was surrounded by lung parenchyma. A nodule 
was considered attached when the length of the contact surface with other pul­
monary structures (fissure, vessel or pleura) was more than 50% of the diameter 
of the nodule at volume-rendered reconstruction or on transverse images. A nod­
ule was regarded spherical when its maximum diameter was smaller than twice its 
minimum diameter; otherwise, it was considered non-spherical. A nodule was 




The rate of satisfactory segmentation was compared between P1 and the other two 
software packages (P2 and P3) by using the Fisher exact test. The Kolmogorov­
Smirnov test was used to determine the normality of the distribution of nodule 
volumes. Nodule volume and VDT were compared between P1&P2 and between 
P1&P3 by using the Wilcoxon signed ranks test. The percent difference in volume 
between P1 and the other two packages was defined as a percentage of the differ­
ence between two measuring volumes divided by the mean of the two values. The 
kappa test was used to determine the agreement for nodule size categories and 
growth categories between P1 and the other two software packages (P2 and P3). 
All statistical analyses were performed using SPSS software (version 18.0; SPSS, 
Chicago, IL, USA). 
Table 1 Overview of satisfactory initial segmentation of baseline lung nodules by soft-
ware package P, , P2 and P3, according to nodule characteristics 
Satisfactory in itial segmentation p-value 
n 
P1 P2 pl P1 & P2 P1 & P3 
Location 
Peripheral 1 25 1 20 (96.0) 1 06 (84.8) 1 1 0 (88.0) n.s. <0.05 
Non-peripheral 22 1 8  (81 .8) 18 (81 .8) 20 (90.9) <0.05 n .s. 
Attachment 
lntraparenchymal 78 76 (97.4) 73 (93.6) 78 ( 1 00.0) n.s. n .a. 
Fissure-attached 1 1  9 (81 .8) 1 1  ( 1 00.0) 1 1  ( 1 00.0) n.a. n.a. 
Vessel-attached 33 28 (84.8) 1 8 (54.5) 1 7  (51 .5) n.s. n .s. 
Pleural-based 25 25 ( 100.0) 22 (88.0) 24 (96.0) n.a. n .a. 
Shape 
Spherical 141 1 33 (94.3) 1 20 (85. 1 )  1 25 (88.7) <0.05 <0.01 
Non-spherical 6 5 (83 .3) 4 (66.7) 5 (83.3) n.s. n .s. 
Edge 
Smooth 141 1 34 (95.0) 1 21 (85.8) 126 (89.4) <0.05 <0.01 
Non-smooth 6 4 (66.7) 3 (50.0) 4 (66.7) n.s. n .s. 
Total 147 1 38 (93.9) 1 24 (84.4) 1 30 (88.4) <0.01 <0.05 
Unless otherwise indicated, data are n umbers of nodules, with percentages in parenthe­
ses. P-values for agreement based on Fisher exact test, comparing P1&P2, and P1&P3. 




In the 50 participants randomly selected from the baseline round of the NELSON 
study, 44 subjects (38 male / 6 female) had at least one lung nodule on the base­
line CT examination. 147 nodules in 25 participants were found on both baseline 
and follow-up CT examinations. The mean (± SD) age of 25 participants was 62 ± 7 
years. The number of nodules per subject ranged from 1 to 19. Thirteen partici­
pants had more than 5 nodules. Of the 147 nodules, 125 were located in the pe­
riphery, 141 were spherical and 141 had a smooth edge (Table 1). Besides 78 in­
traparenchymal nodules, 11, 33 and 25 nodules were fissure-attached, vessel­
attached and pleural-based, respectively. Initial segmentation at baseline was 
evaluated to be satisfactory in 93.9% of 147 nodules using software P1, 84.4 % us­
ing P2, and 88.4% using P3. Significant difference was found in percentage of sat­
isfactory segmentation between the three packages (p < 0.01), based on evaluation 
of agreement in the nodules that were satisfactorily segmented by the different 
software packages. Only half of vessel-attached nodules were satisfactorily seg­
mented by software P2 (54.5%) and P3 (51.5%) versus 84.8% for P1. Especially in 
case of smooth and spherical nodules, the reference software yielded a better ini­
tial segmentation rate than P2 and P3 (Table 1). 
Table 2 Comparison of nodule volume at baseline and volume doubling time (VDT) at 
follow-up between three software packages 
Software Median In itial Median final Median VDT, days package volume*, mm3 volume*, mm3 
P, 37.7 (21 .4-62.8) 37.3 (21 .4-64.7) 297 (-590.3-777.5) 
P2 56.0 (38.0-89.0) 52.0 (37.0-87.0) 356 (-599.3-914.2) 
P3 64.4 (42.7-1 08.4) 62.2 (427.-93.8) 265 (-670.8-91 8.8) 
Unless otherwise indicated, data are volumes of nodules with 25th and 75th percentile in 
parentheses. 
* Wilcoxon signed ranks test; comparison between P1&P2, and between P1&P3; for both 
comparisons, p value less than 0 .001 
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The distribution of the nodule volumes was skewed for all three software 
packages (Kolmogorov-Smirnov test: p<o.001). The median of the initial and final 
baseline volume as well as the VDT was determined for all three software pack­
ages (Table 2). The mean percent difference between initial and final volume was 
0.5% for software P1, 4.9% for P2 and 7.2% for P3. Significant difference was found 
in the volume between P1 and the other two packages (p < 0.001). Compared to 
the reference software P1, P2 overestimated the volume by 38 ± 24%, and P3 by 50 
± 22%. No significant difference was found in VDT between P1&P2 and P1&P3; 
however the interquartile range in VDT was wide. 
The median of the final baseline volume for the three software packages by 
nodule characteristics is shown in Table 3. For nearly all nodule characteristics, 
the volume derived from P2 and P3 was significantly larger than that obtained for 
the reference software. Only for non-smooth nodules (in total 6 in the current 
selection) , no significant volume difference was found. 
Table 3 The median final volume on baseline scans for the software packages by nod-
ule characteristics. 
Nodule charac-
Median final volume, mm3 P-value 
teristic n 
P1 P2 P3 P1&P2 P1&P3 
Location 
Peripheral 1 25 46.1 (21 .3-6 1 . 1 )  64.3 (37 .8-86.0) 73.4 (42.5-93.8) <0.001 <0.001 
Non-peripheral 22 79.4 (29.3-101 .3) 89.9 (36 8-1 1 1 .5) 98.8 (41 .9-1 32 4) <0.01 <0.0 1  
Attachment 
lntraparenchymal 78 45.7 (20.3-52. 1 )  63.3 (36 8-78,3) 70.0 (41 ,5-85,6) <0.001 <0.001 
Fissure-attached 1 1  5 8  7 ( 1 6.7-87.6) 87.0 (35.0-1 24.0) 90.4 (37.6-1 38.6) <0.01 <O 01 
Vessel-attached 33 60.9 (31 .5-76.5) 71 .0 (42.0-92.5) 92. 1 (56.3-1 1 5.3) <0.01 <0.001 
Pleural-based 25 5 1 .6 (23.0-63,3) 71 . 1 (35.5-90,5) 73.9 (39 6-93 8) <0.001 <0,001 
Shape 
Spherical 1 4 1  50,6 (21 .7-63,7) 67.2 (37.0-87.0) 76.3 (42.7-93 8) <0,001 <0.001 
Non-spherical 6 62.8 ( 1 8.8-1 1 1 .2) 88.8 (40.8-1 60. 8) 97.4 (36.8-201 ,8) <0.05 <0.05 
Edge • 
Smooth 1 41 46 4 (21 . 1 -60. 1 )  64.0 (37 0-83.5) 72.8 (42 0-91 .7) <O 001 <0.001 
Non-smooth 6 161  8(53.1 -247.2) 1 65.3 (78.0-237.0) 1 80.9 (70 4-254.9) n.s. n.s. 
Data are median volumes of nodules with 25th and 75th percentile in parentheses. 
Wilcoxon Signed ranks test was used to compare the median final volume between 
P1 &P2 and P1&Pa within every individual nodule characteristic. 
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Table 4 shows the categorization of pulmonary nodules according to size and 
VDT, and agreement between software packages. At baseline, there was consensus 
on nodule size categorization for 117 nodules (79.6%) when comparing software 
P1& P2 and 109 (74.1%) when comparing P1& P3 (Table 4) . At follow-up, P1& P2 
showed consensus on nodule VDT categorization in 40 (47.1%) nodules, and P1& 
P3 in 38 (44.2%) nodules. There was moderate agreement for nodule size catego­
rization at baseline and growth determination at follow-up between P1 and the 
other two software packages (P2 and P3). The categorization according to VDT at 
follow-up showed fair agreement between P1&P2 and P1&P3. 
Table 4 Distribution of nodule size categories and growth categories according to three 
software packages 
N ., Kappa-value 
• a. • a. "' ca "' ca  
::, -"' a.  ::, -"' a.  
C C C C: 
P, P2 P3 (lJ (lJ (lJ (lJ "' (lJ  "' Q)  P,&P2 P,&P3 § �  5 �  
(.) Q) (.) Q) .0 
Size category at baseline 0.598 0 514 
Negative (< 50 mm3) 96 70 58 68 58 
Indeterminate (50-500 mm3) 51 77 89 49 51 
Positive (> 500 mm3) 0 0 0 0 0 
Growth in follow-up 0.539 0 427 
No growth 62 61 61 45 41 
Growth 85 86 86 69 65 
VDT in follow-up 0.388 0.330 
GROWCAT A (>600 days) 43 52 51  23 23 
GROWCAT B (400-600days) 23 1 3  1 3  3 
GROWCAT C (<400 days) 1 9  21 22 14 14 
Unless otherwise indicated, data are numbers of nodules. 




<0.001 <0 001 
<0.001 <0.001 
<0.001 <0.001 
This study shows that satisfactory nodule segmentation was automatically ob­
tained in the majority of lung nodules for all three software packages. We recently 
found only very small differences between nodule volumes for software package P1 
and actual volumes in a phantom study [9]. Thus, P1 was used as reference for 
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comparison. The measured nodule volumes were significantly different for the 
other two software packages with overestimation of nodule volumes of 38% to 
50% compared to the reference software package. Despite volume differences, 
agreement in baseline categorization of nodules according to volume was still ob­
tained in 74-80% of cases. However, the consensus on the VDT categorization at 
follow-up was less than 50 % when P2 and P3 were compared to the chosen refer­
ence, P1. 
Because of recent reports on the value of VDT for the determination of ma­
lignancy f 4, 11-13]. there is now widespread interest in the use of volumetric soft­
ware. Compared to nodule volumetry, the repeatability of diameter measurements 
has been found to be suboptimal [14,15]. Likely, this is related to the fact that two­
dimensional measurements are relatively insensitive to size change. For example, 1 
mm increase in the cross-sectional diameter of a 10-mm spherical nodule on two 
consecutive scans corresponds to a 10% increase in diameter but a 33% increase in 
volume. If the two examinations were performed 3 months apart, the volume in­
crease indicates a VDT compatible with malignancy (VDT <400 days). However, 
the diameter change would still be considered to fall in the range of measurement 
variation. In addition, volume changes estimated from two-dimensional meas­
urements may miss asymmetric growth [16]. The most common approach for 
measuring the volume of lung nodules is based on a grey-level threshold, that al­
lows a user to segment lung nodules from the background voxels [17]. Since at­
tenuation information is not sufficient to distinguish nodule boundaries from at­
tached vessels, most semi-automated methods incorporate morphologic operators 
[18]. 
The only article so far that has assessed different software packages for 
volumetric evaluation of lung nodules, is by de Hoop et al. [ 6]. Both in our study 
and in the study by de Hoop et al., the software types were anonymized. Thus, we 
cannot directly compare our results for specific software packages to those of de 
Hoop. In this study, six software packages were compared, in which the accuracy 
of segmentation varied from 71% to 86% prior to manual correction. In our study, 
initial segmentation by the three software packages was visually judged to be sat­
isfactory for most of the nodules (range, 84.4%-93.9%). The segmentation rates 
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for software packages in the study by de Hoop were somewhat lower than in our 
study. This is likely due to a higher percentage of smooth, round, intraparenchy­
mal nodules in our study. Although the visual appearance of segmentation was 
correct in the majority of cases for all software packages in our study, P2 and P3 
resulted in larger nodule volumes when compared to P1. The most likely reason 
for the difference in volume lies in differences in segmentation of border tissue 
where a 1 pixel increase in segmented surface can already have considerable impli­
cations for the measured volume. 
It is obvious that segmentation that includes surrounding structures or does 
not include part of a nodule may lead to inaccurate measurements and wrong 
management decisions [ 6]. A considerable part of segmentation errors in com­
pletely automatic measurement is due to adjacent structures. For example, juxta­
pleural and juxtavascular nodules have been shown to exhibit higher volume 
measurement variability than well-circumscribed intraparenchymal nodules [8,15]. 
In this study, for two of the three software packages, the segmentation of nearly 
half of the vessel-attached nodules was initially unsatisfactory. Compared to 
purely-intraparenchymal nodules, attached nodules have been found to have a 
lower risk of malignancy. In a NELSON sub-study by Xu et al. [10] reported that 
no malignancies were found at 1-year follow-up in smooth or attached solid inde­
terminate non-calcified nodules. As cancer risk may be negligible the importance 
of measurement variability in attached nodules is likely less in the clinical practice. 
In some studies, irregular or spiculated nodules showed increased volume meas­
urement variability compared to smooth nodules [19,20]. We found that the per­
centage of satisfactory segmentations of non-smooth nodules was low for all three 
packages. However, only 6 non-smooth nodules were included in the current 
study. Nevertheless, our further results indicate that nodule morphology influ­
ences volume measurement variability, 
In the study by de Hoop et al. [6], significant differences in nodule volume 
were found among software packages, although the actual differences in volu­
metry between software packages were not reported in detail. Similarly, our re­
sults indicate that the volumes obtained from nodule evaluation software pack­
ages were significantly different. Recent results from a phantom study indicate 
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only a small underestimation of nodule volume (overall, -4.9%) by LungCARE 
software (P1) compared to actual volumes [9]. These differences between Lung­
CARE results and actual volumes were an order of magnitude smaller than the 
differences found between LungCARE and the other two software packages in the 
current study. This may suggest that software P1 yields more accurate volumetry 
results than P2 and P3. However, the findings from the phantom study cannot be 
extrapolated with certainty to clinical practice, as the actual size of the detected 
lung nodules in subjects is unknown in contrast to a phantom situation. Thus, we 
cannot determine a reference standard based on our results. Our findings do 
point to a significant influence of software packages on nodule categorization and 
follow-up management. Using P2 and P3, more nodules ended up in a higher 
category of nodule management, potentially leading to unnecessary diagnostic 
procedures, patient anxiety, morbidity and costs. To reduce influence in categori­
zation based on changes in software package, consecutive screening evaluations 
should be performed with the same semi-automated software package. 
There is limited public knowledge of the algorithms used to perform nodule 
segmentation. As described in the Material and Methods, all software packages 
used a similar one-click approach for the segmentation. Based on published de­
tails about the different algorithms they all three rely on a quite similar and com­
parable multi-step approach [21-23]. The first step uses intensity/density based 
algorithm using the tissue densities in Hounsfield unit values combined with a 
region growing or connected components algorithm starting from the click point. 
The second step consists of constrained morphological operations that limit the 
actual volume and separate the nodule from the surrounding structures based on 
properties such as roundness. Based on the segmentation result, the volume is 
determined in a third and final step. In this final step the description of the On­
coTreat software [22) deviates from the other two in that it specifically mentions 
the use of a variation of the partial volume method for volume calculation which 
involves a three region approach to avoid partial volume effects on the volume. 
Other differences in the actual measurement of the volume are most probably due 
to subtle differences in the thresholds and specific criteria used in the different 
steps of which some are also user definable and correctable when a non-optimal 
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segmentation occurs. A definite conclusion about the influence of the different 
steps of the algorithms used is however not feasible since the exact algorithms 
used to determine the segmented area are not disclosed by the respective compa­
nies. 
On serial examinations, lung nodule measurements derived from CT are 
used to evaluate size change to predict the likelihood of malignancy and to moni­
tor the interval of follow-up [3]. A change in size is considered highly important 
for suggesting a diagnosis or management for follow-up since malignant nodules 
generally grow fast. Although no significant difference in VDT was found between 
the software packages, the agreement in VDT categorization was only fair. There­
fore, using different software packages could greatly influence nodule manage­
ment decisions especially for intermediate-sized nodules on consecutive examina­
tions. We consider validation and calibration of software for lung nodule volu­
metry of utmost importance to limit variability and inaccuracy in nodule man­
agement. The validity and reliability of software packages could be improved by 
calibration against a publicly available database of CT datasets with nodules of 
known size. 
In this study all nodule measurements were performed by one radiologist 
with more than 10 years experience, because no significant benefit has been found 
for consensus double reading of lung nodule volume measurements [24] and the 
inter-observer variability is negligible by using semi-automated volumetry [25]. 
Furthermore, the intra- and inter-observer reproducibility of visual assessment of 
segmentation accuracy is high [6]. 
The current study concerns lung nodules found as part of a CT lung cancer 
screening program. Our results do not apply to a non-screening situation. We 
have previously shown that compared to size, morphological characteristics of 
screen-detected nodules are of minor importance to distinguish between benign 
and malignant nodules [10, 26]. However, in clinical decision making, other fac­
tors can play an important role. For example, a recent clinical study questioned 
the use of CT-derived growth rates of as the only determinant to decide whether 
or not to perform biopsy [27]. Further investigations are needed to evaluate the 
role of volumetry and VDT of pulmonary nodules in clinical settings. 
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The main limitation of the current study is the relatively small sample of in­
dividuals. However, the number of nodules was still considerable, and there was a 
fair distribution in the types of nodules commonly encountered in lung cancer CT 
screening. We suggest larger studies should confirm our findings. A second limi­
tation is that we only included solid lung nodules. These are the most prevalent 
type of nodules in lung cancer screening. Management of solid nodules is based 
on size and VDT. Features that need to be assessed for determination of manage­
ment of sub-solid nodules are still under investigation. The vast majority of the 
nodules in our study were smooth and round. Lung cancer cases more often have 
an irregular contour and lobulated or spiculated shape [26] . However, this reflects 
findings in lung cancer screening, as this was also the most prevalent nodule type 
in a larger sample of 658 screened individuals with 891 indeterminate lung nod­
ules [10] .  The fact that the percentage of smooth, round nodules was somewhat 
higher in the current study is considered to be due to random sampling. Also, as 
the pathology of the nodules was unknown, we cannot draw conclusions on the 
accuracy of VDT assessment for distinguishing between benign and malignant 
nodules. A study on optimization of VDT cutoff criteria was recently published 
[28] . Lastly, we only evaluated three software packages. Whether the results found 
for these software packages are a good representation of the results of other avail­
able lung nodule volumetry software, is unknown. 
In conclusion, software packages for lung nodule evaluation yield significant 
differences in volumetric measurements and VDT. This variation affects the clas­
sification of lung nodules in baseline and, especially, follow-up examinations. 
Overestimation of volumetry may result in false-positive conclusions with poten­
tial serious consequences for the patient. Further standardization of software used 
for nodule volumetry and VDT assessment is needed to optimize nodule man­
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To retrospectively identify features that predict disappearance of solid indetermi­
nate (size 50-500 mm3) ,  intraparenchymal nodules detected at baseline in a lung 
cancer computed tomography ( CT) screening study among individuals at high 
risk for lung cancer 
Materials and Methods 
The study was institutional review board approved. Participants gave informed 
consent. Participants with at least one non-calcified solid, indeterminate, in­
traparenchymal nodule (size 50-500 mm3) at baseline were included (n=964 nod­
ules in 750 participants). According to protocol, indeterminate nodules were re­
examined by 3-month follow-up CT. Regular repeat screening rounds were at year 
2 and 4. A nodule was defined as resolving if it had disappeared on a subsequent 
CT. Nodule resolution was regarded as spontaneous, not the effect of treatment. 
CT features of resolving nodules and non-resolving (stable and malignant) nod­
ules were compared by generalized estimating equations analysis. 
Results 
During subsequent screening rounds, 10.1% (97/964) of the nodules disappeared, 
77.3% (n = 75) of these before the 3-month CT and 94.8% (n = 92) before the sec­
ond-round screening. Non-peripheral nodules were more likely to resolve than 
peripheral nodules (odd Ratio [OR]: 3.16; 95% CI:  1.76-5.70) Compared to smooth 
nodules, nodules with spiculated margin showed the highest probability of disap­
pearance (OR: 4.36; 95% CI: 2.24-8.49). 
Conclusions 
About 10% of solid intraparenchymal pulmonary nodules of intermediate size 
found at baseline lung cancer screening resolves during follow-up. Three quarters 
of resolving nodules have already disappeared at the 3-month follow-up CT which 
is performed for intermediate size lung nodules. Resolving pulmonary nodules 




With the widespread use of multi-detector computed tomography (CT) in daily 
clinical practice and its use in lung cancer screening, the number of detected 
pulmonary nodules has increased as compared to standard chest X-ray examina­
tions. Up to 66% [1] of participants enrolled in CT screening trials has at least one 
small-to-intermediate-size pulmonary nodule. Solid lung nodules are the most 
common type of nodules found in lung cancer screening [2, 3]. Most indetermi­
nate nodules are benign [2], and may represent granulomatous or infectious le­
sions, or enlarged lymph nodes. The question arises whether it is possible to iden­
tify specific features of nodules that will subsequently resolve in order to avoid 
unnecessary repeat CT scans and work-up as well as public health costs and anxi­
ety. 
Four studies studied resolving nodules [4-7]. Only one focused on solid lung 
nodules [4]. A substantial part of the follow-up examinations in this study were 
performed with thicker slices, which may miss small rest lesions. Also, there was 
no comparison to non-resolving nodules. 
The Dutch-Belgian randomised lung cancer screening trial (Dutch acronym 
NELSON) is the first in which nodule management is based on CT-derived vol­
ume and volume-doubling time (VDT) assessment [8]. Volumetric measurement 
is more accurate than diameter measurements [9, 10]. At baseline screening, a 
nodule with volume > 500 mm3 led to referral for workup. For intermediate sized 
solid nodules (50-500 mm3, corresponding to 4.6-9.8 mm in diameter} ,  so-called 
indeterminate nodules, repeat CT was performed after 3 months. Indeterminate 
nodules were then divided into those that showed no or less than 25% growth, 
leading to a regular next-round screening, and those that showed greater than 
25% growth, leading to referral for workup and diagnosis [8, 11]. Next-round CT 
results (year 2, 4 and 6} were based on volume measurements for newly detected 
nodules and growth evaluation of previously detected nodules. 
The purpose of our study was to retrospectively identify features that predict 
complete resolution of non-calcified solid indeterminate, intraparenchymal nod-
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ules detected at baseline in a lung cancer CT screening study among individuals at 
high risk for lung cancer. 
Materials and Methods 
Study population 
This study was performed in the context of the NELSON trial, (trial registration 
number: ISRCTN63545820), which was approved by the Dutch Healthcare Com­
mittee and the ethics board at each participating center. All participants gave 
written informed consent at study entry. The current retrospective evaluation fell 
under the terms of the informed consent. Participants were between 50 and 75 
years of age and were recruited via population registries through mail. Only cur­
rent or former smokers with a smoking history of > 15 cigarettes/day for > 25 years 
or > 10 cigarettes/day for > 30 years were included. People with a history of pneu­
monectomy, breast cancer, melanoma or hypernephroma were not included. Peo­
ple with a history of other types of cancer were only eligible if they were curatively 
treated at least 5 years ago without signs of recurrence at the time of inclusion [12] . 
Participants underwent low-dose multidetector computed tomography (MDCT) 
screening at baseline (first round), 1 year later (second round) and 3 years later 
(third round), and received extra low-dose follow-up MDCT in case of an inde­
terminate lung nodule. Previously, the NELSON screening protocol was published 
in detail [8] . 
Our study was based on all baseline examinations of NELSON project. In to­
tal, 7,557 participants underwent baseline screening between April 2004 and De­
cember 2006 [2]. According to NELSON protocol, non-calcified solid nodules 
were classified into categories based on size [8]. A previous study showed that the 
rate of malignancy in attached indeterminate lung nodules was negligible [13] . 
Therefore, in the current study, only solid intraparenchymal (i.e. surrounded by 
lung parenchyma) nodules with volume between 50 - 500 mm3 (i.e. intermediate 
size) at the baseline screening were included. Larger nodules were referred to the 
pulmonologist and smaller nodules did not receive extra follow-up. An indetermi­
nate result led to an extra follow-up CT 3 months after baseline. If no or slow 
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growth of the nodule was found, subjects subsequently underwent the standard 
repeat screening examination. Indeterminate nodules without significant growth 
at least two years after baseline or with benign result on histological analysis were 
regarded as benign. Subjects with a fast growing nodule (volume doubling time 
[VDT] <400 days) were referred to pulmonologists for further diagnosis. 
Nodules with less than 2 years follow-up after baseline, were excluded. Also 
participants with malignancies other than primary lung cancer were excluded. 
CT scanning protocol 
At all four screening sites 16-MDCT scanners were used (Sensation-16, Siemens 
Medical Solutions, Forchheim, Germany, or Mx8ooo IDT or Brilliance 16P, Philips 
Medical Systems, Cleveland, OH, USA). Scanning of the entire chest was per­
formed in caudo-cranial direction. Scan data were obtained in spiral mode, with 
16 x 0.75 mm collimation and 1.5 pitch. No contrast media was used. Low-dose 
settings were applied depending on body weight (<50 kg, 50-80 kg and >80 kg}, 
with kVp settings of 80-90, 120 and 140 kVp, respectively, to achieve a volume CT 
dose index (CTDiv01) of approximately o.8 mGy, 1.6 mGy and 3.2 mGy, respectively. 
The mAs settings were adjusted accordingly, depending on the system used. To 
minimise breathing artefacts, CT-scans were performed at suspended maximal 
inspiration after appropriate instruction of the subjects. Data were reconstructed 
at 1.0-mm slice thickness, with 0.7-mm reconstruction increment. Repeat exami­
nations were performed with the same technical parameters in low-dose setting as 
used at baseline. 
Image Reading 
All CT images were read twice independently [2, 8]. First readings were done by 
one of thirteen radiologists with experience in thoracic CT varying from 1 year to 
more than 20 years. Second readings were done by one of two radiologists (Y.W., 
Y.R.Z.) with at least 6 years experience. In case of discrepancy between first and 
second reader, a third radiologist (M.O.) with more than 15 years experience in 
thoracic CT arbitered. Discrepancy in nodule categorization between first and 
second reading was found for 43 lesions in 37 individuals. 
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The Syngo Lungcare© (Leonardo© workstation, Somaris/5 VB 10A Siemens 
Medical Solutions, Erlangen, Germany) software package designed to aid radiolo­
gists in diagnosing pulmonary nodules was used in addition to visual evaluation. 
Baseline and follow-up images were reviewed and displayed simultaneously on 
one workstation. Lung windows were assessed at a width of 1600 and a level of -
700 Hounsfield Units. All images were interpreted both in lung window and me­
diastinal settings. First, the reader had to detect and then mark the pulmonary 
nodule by a mouse click. Subsequently, the program automatically defined the 
volume of interest of the nodule. A three-dimensional template was generated, 
optimally representing the nodule. If needed, manual modification of the segmen­
tation was performed. A second mouse click initiated the automated volume 
measurement program. Semi-automated measurements are highly reproducible 
for the vast majority of nodules [14]. In 86% of >4000 screen-detected solid nod­
ules, double reading yielded the same volume. Volume differences > 15% were 
found in only 4% of nodules [14] . If measured volume differed between first and 
second reader, results from the second reader were used for further analyses. 
Nodule characteristics 
Nodules were classified as benign or malignant based on histology or benign 
based on stable volume for > 2 years after baseline. In addition, they were classi­
fied based on distance to costal pleura (peripheral or non-peripheral), shape 
(spherical or non-spherical), and margin (smooth, lobulated, spiculated or irregu­
lar) [8, 13, 15] . 
The distance to costal pleural was < 1/3 from total distance hilum-costal 
pleura for peripheral nodules, > 1/3 for non-peripheral nodules. A nodule was re­
garded non-smooth when its margin was lobulated, irregular or spiculated, and 
smooth otherwise [15, 16]. A nodule was regarded spherical when its maximum 





At follow-up examinations, images were compared with the previous screening 
round. A nodule was defined as completely resolving if it had disappeared on a 
follow-up examination, otherwise, it was considered non-resolving. In the NEL­
SON study, 25% change in nodule volume is used to differentiate real change from 
measurement variation [u]. Thus, decrease in volume � 25% was regarded as ac­
tual decrease in size. Nodules that decreased in size, but did not disappear, were 
regarded as non-resolving as nodules that decrease at some point, can still even­
tually turn out to be malignant [17]. Nodule resolution was regarded as spontane­
ous, not the effect of any treatment, since antibiotic therapy was not part of the 
nodule management protocol. 
Statistical Analysis 
Generalized Estimating Equation analyses with a logit link function and a bino-
mial distribution were performed to assess whether nodule characteristics were 
related to disappearance at 3-month follow-up CT, and at the regular screening 
CT rounds at year 2 and 4. For distance to costal pleura, shape and margin the 
odds ratios (ORs) and 95% confidence intervals (95%-CI) were estimated in uni­
variate analyses. Then, multivariate analysis of the combined factors was per­
formed, adjusting for the potential confounding effects of age and gender. Chi­
square testing was used to compare the rate and timing of disappearance for nod­
ules with maximal transverse diameter < 8 mm and � 8 mm [18], based on semi­
automated volumetry. A p s 0.05 was considered to indicate a statistically signifi­




At the baseline examination, 1059 solid intraparenchymal nodules with volume 
between 50 - 500 mm3 were found in 805 participants. 95 nodules in 55 partici­
pants were excluded. A total of 964 nodules in 750 (648 men, 102 women) partici­
pants could be included (Figure 1). The mean (± standard deviation) age of these 
participants was 60 ± 6 years. Ninety-seven (10.1%) nodules in 75 participants dis­
appeared during follow-up. In 6i of 75 participants, one resolving nodule was 
identified. The other subjects had 2-5 resolving nodules. Of the nodules that re­
solved, 75/97 (77.3%) had disappeared at 3 months, another 17/ 97 (17.5%) at year 2 
screening, and another 5/97 (5.2%) at year 4 screening. 
1 059 solid intraparenchymal nodules in 
805 participants at baseline 
867 (89.8%) nodules in 695 
participants did not disappear: 
• 840 (96.9%) benign 
• 27 (3. 1 %) malignant 
95 nodules in 55 participants were excluded: 
• 88 (52 participants): no histology obtained 
and 
< 2 years follow-up 
• 6 (2 participants): metastatic disease 
• 1 (1 participant): mesothelioma 
97 ( 1 0.1 %) nodules in 75 participants 
disappeared: 
• 75 (77.3%) disappeared at 3 month 
• 1 7  ( 1 7.5%) disappeared at year 2 
• 5 (5.2%) disappeared at year 4 
Figure 1 Overview of nodule selection from the NELSON study 
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Of 867 non-resolving indeterminate nodules at baseline, 105 (12.1%) showed 
>25% volume decrease during follow-up. Forty-seven (5.4%) nodules had addi­
tional workup due to short VDT in follow-up rounds. In 27 nodules (3.1%) lung 
cancer was diagnosed; 9 at the examination three months after baseline, 9 in the 
regular second-round examination, 2 one year after the regular second-round 
screen, 6 in the regular third-round examination and 1 one year after the regular 
third-round screen. The remaining 20 nodules comprised false-positive results; no 
malignancy was confirmed and the regular next-round CT scan was scheduled 
(Figure 1). 
Table 1 Characteristics of resolving and non-resolving nodules (n in total=964) 
Total Resolving Non-resolving Non-resolving Non-resolving benign malignant 
Total 964 97 ( 1 0. 1 ) 867 (89.9) 840 (96.9) 27 (3 . 1 )  
Distance to costal pleural 
Peripheral 828 68 (8.2) 760 (91 .8) 735 (96.7) 25 (3.3) 
Non-peripheral 1 36 29 (21 .3) 1 07 (78.7) 1 05 (98. 1 )  2 ( 1 .9) 
Shape 
Spherical 816 88 (1 0.8) 728 (89.2) 703 (96.6) 25 (3.4) 
Non-spherical 148 9 (6. 1 )  1 39 (93.9) 137 (98.6) 2 (1 .4) 
Margin 
Smooth 680 53 (7.8) 627 (92.2) 618 (98.6) 9 (1 .4) 
Lobulated 1 95 22 ( 1 1 .3) 1 73 (88.7) 165 (95.4) 8 (4.6) 
Spiculated 63 17 (27.0) 46 (73.0) 36 (78.3) 1 0 (21 .7) 
Irregular 26 5 (1 9.2) 21 (80.8) 21 ( 1 00) 0 (0) 
Unless otherwise indicated, data are numbers of nodules, with percentages in parenthe-
ses. 
The characteristics of resolving and non-resolving nodules are shown in Ta­
ble 1. Most lung nodules, whether resolving or not, were peripheral, smooth and 
spherical. Resolving nodules were more frequently non-peripheral than non­
resolving nodules. Relatively less resolving nodules were smooth and more had a 
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spiculated margin. Non-resolving malignant nodules, however, also tended to be 
less often smooth, and more frequently spiculated (for examples of resolving nod­
ules see Figure 2). 
Table 2 Odds ratios showing the association between baseline characteristics and nod­
ule disappearance of solid intraparenchymal nodules detected at baseline (n = 964) 
Odds Ratio* 
Nodule characteristic Univariate Multivariate at baseline 
Distance to costal pleural p < 0.001 p < 0.001 
Peripheral 
Non-peripheral 3.03 (1 .73-5.29) 3 . 1 6  ( 1 .76-5.70) 
Shape P = 0. 1 2  P = 0 . 13  
Spherical 
Non-spherical 0.54 (0.24-1 . 1 9) 0.53 (0.23-1 .2 1 )  
Margin t :j: 
Smooth 
Lobulated 1 .50 (0.83-2.73) 1 .59 (0.89-2.86) 
Spiculated 4.37 (2.25-8.48) 4.36 (2.24-8.49) 
Irregular 2.82 (0.86-9.22) 3. 1 2  (0.75-12.99) 
* Data in parentheses are 95% Confidence Intervals. In the Multivariate Analyses, the nodule char­
acteristics were included, as well as participant age and gender as potential confounders. 
t Pairwise comparison within the univariate analysis showed a statistically significant difference 
between spiculated and lobulated nodules (P<0.01 (P=0.005)) and between spiculated and smooth 
nodules (P<0.001 ) ((Smooth lobulated P=0. 1 8, smooth irregular P=0.09, lobulated irregular 0.32, 
speculated irregular 0.49)). 
:j: Pairwise comparison within the multivariate generalized mixed model showed a statistically signifi­
cant d ifference between spiculated and lobulated nodules (P<0.01 (P=0.008)) and between spicu­
lated and smooth nodules (P<0.00 1 )  No significant d ifferences were found between smooth and 
lobulated (P=0. 1 2), smooth and irregular (P=0. 1 2) ,  lobulated and irregular (P=0.37), and speculated 




Figure 2 Examples of resolving nodules (a) a smooth and round nodule with baseline 
volume 1 06.2 mm3 disappeared at 3-month follow up, (b) a lobulated nodule with base­
line volume 1 67.3 mm3 disappeared at 3-month follow up. 
Odds ratios for factors related to nodule disappearance are shown in Table 2. 
Significant differences were found in distance to costal pleura and margin. Non­
peripheral nodules had a 3.16 times higher chance to disappear at 3 months than 
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peripheral nodules (95%CI : 1.76-5.70) . Pairwise comparison showed significant 
difference in probability of resolution between spiculated and lobulated nodules 
(p < 0.01) and between spiculated and smooth nodules (p < 0.001). Although not 
statistically significant, nodules with non-spherical shape tended to have a lower 
chance of resolution than spherical nodules (OR: 0 .53; 95%CI : 0.23-1.21) . 
In analysis by maximum diameter (< 8 mm versus � 8 mm), the rate of dis­
appearance was lower in nodules < 8 mm than in nodules � 8 mm (Table 3A). Lar­
ger nodules tended to disappear already in higher percentage before the short­
term follow-up CT compared to the smaller nodules (Table 3B). 
Table 3A Nodule resolution according to nodule size 
Total Resolving Non-resolving Non-resolving malignant 
Total 964 97 ( 1 0.1 ) 867 (89.9) 27 (3 . 1 )  
Maximal transverse diameter 
< 8  mm 751 58 (7.7) 693 (92.3)* 14 (2.0) t 
2: 8 mm 213  39  ( 1 8.3) 1 74 (81 .7) 1 3 (7.4) 
* Significant difference between resolving and non-resolving nodules according to nodule size (P < 
0.001 ) 
t Significant difference between non-resolving and non-resolving malignant nodules according to 
nodule size (P<0.001 ) 
Table 38 Moment of resolution according to nodule size 
Total resolving 
Total 97 (1 0.1 ) 
Maximal transverse diameter 
< 8 mm 
2: 8 mm 
1 00 
58 (7.7) 
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From 2004 to 2006, 805 of 7557 participants (10.7%) in the NELSON study had at 
least one solid intraparenchymal nodules with volume between 50 - 500 mm3. Of 
the 964 nodules that were included, 97 (10.1%) had disappeared in the follow-up 
examinations. While the majority of solid indeterminate, intraparenchymal pul­
monary nodules found at baseline lung cancer screening does not resolve, three 
quarters of the nodules that do resolve can be identified by short-term repeat CT. 
Non-peripheral nodules were three times more likely to resolve than peripheral 
nodules. Spiculated nodules had a four times higher chance to disappear than 
smooth nodules. 
Only few studies in the field of lung cancer screening have focused on disap­
pearing nodules. Diederich et al. [4] studied 107 resolving nodules in 56 individuals, 
Lee et al.[5] studied 126 resolving part-solid nodules in 93 subjects, Felix et al. [6] 
evaluated 32 resolving ground-glass opacities in 18 subjects, and Mario et al.[7] 
assessed 18 out of 76 ground-glass opacities resolving. Non- and part-solid nod­
ules have other characteristics than solid nodules. 
In the study by Diederich et al.[4], the number of resolving nodules per indi­
vidual was 2.38 for participants who had at least one resolving nodule. In that 
study, the maximum diameter of completely resolving nodules was � 5 mm in 56 
of the 107 (52%) nodules. In case of nodules < 5 mm, even those that persist have 
negligible risk of malignancy [19]. In our study, including nodules with volume > 
50 mm3 (corresponding to 4.6 mm diameter), only 2/964 (0.002%) nodules were 5 
mm or less. Diederich et al. [4] found the majority of completely resolving nod­
ules in participants of young age (< 50 years). The risk of lung cancer development 
increases with aging [20]. In this study, the main age of subjects was 60 ± 6 years, 
with an age distribution comparable with the overall age distribution of the NEL­
SON study [2]. Therefore, our results mainly concern the behaviour of lung nod­
ules at intermediate-risk (based on size and age) of being malignant. 
In the study by Diederich et al. more than one resolving nodule was found in 
34% individuals, and in one subject, > 13 resolving nodules were identified. In our 
study, due to the exclusion of small and large nodules, the number of resolving 
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nodules per individual was lower (1.32 per individual). Twenty percent of the sub­
jects had more than one nodule that disappeared (range 2-5) [4]. Besides the ex­
planations of nodule size and age, another explanation could be that these nod­
ules are the end stage from benign diseases as multiple nodules are often seen in 
emphysema or inflammation. 
Even in patients at high-risk to develop lung cancer the vast majority of inci­
dentally detected nodules are benign [21] . These benign nodules are probably 
caused by focal infection or inflammation and often resolve completely or de­
crease in size at short-term follow-up either after therapy with antibiotics or 
spontaneously [22]. Libby [23] from the Early Lung Cancer Action Project (ELCAP) 
reported that 12% of nodules � 5 mm in diameter in participants who had received 
antibiotics had completely resolved within two months after the initial CT in 
baseline screening. Antibiotic therapy was not part of the NELSON protocol. 
Libby et al. [23] reported direct referral for nodules >15mm, so the size of their 
group of nodules (5 - 15 mm), and thereby the risk of infection or inflammation, 
did not differ much from our study (5 - 10 mm). Since the nodule disappearance 
in our study was not the effect of any treatment, our results show a lower percent­
age (8%) of resolving nodules at short term follow-up (3 months). 
It has been demonstrated that a solid, peripheral, subpleural nodule is a spe­
cific benign lesion, and mostly may represent intrapulmonary lymph nodes [16] . 
The main proportion of resolving nodules in this study were peripheral. Both re­
solving and non-resolving nodules were mainly spherical. Nodules with smooth 
margin were numerous in both the resolving and the non-resolving group. How­
ever, the results showed significant differences between resolving and non­
resolving nodules in nodule characteristics. Distance to costal pleural and margin 
were correlated with nodule disappearance. 
The characteristics of nodule edge are one of the important factors in deter­
mining whether a lesion is benign or malignant. However, nodules in benign con­
ditions, such as lipoid pneumonia, tuberculoma, and progressive massive fibrosis, 
may have spiculated margins as malignant nodules [24] . Moreover, a lobulated 
outline is often associated with malignancy, but may be seen in up to 25% of be­
nign nodules [25]. Furuya et al. [26] analysed margin characteristics of pulmonary 
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nodules at thin-section CT and found that 80% of the polygonal nodules were the 
result of inflammatory change and 20% represented primary lung cancer. In the 
study of Takashima et al. [27], concave margin and polygonal shape were both spe­
cific to benign lesions. Our results also show that nodules with non-smooth edges 
disappeared more frequently than smooth nodules. However, non-smooth edges 
are also more frequently found in malignant nodules [28]. So, based on the char­
acteristics of nodule edge, no differentiation can be made between resolving and 
non-resolving malignant nodules. 
The rate and speed of disappearance was higher in baseline-detected nodules 
with a larger diameter (2: 8 mm vs < 8 mm). However, the rate of malignancy was 
also higher. Some benign conditions, like inflammations, more commonly have a 
larger diameter. This may be an explanation for the increased probability of dis­
appearance in nodules with larger maximal transverse diameter. Further stratifi­
cation of indeterminate nodules dependent on diameter did not help in differen­
tiating between resolving and malignant nodules, and, based on our results, can­
not substitute the NELSON volume-based protocol. 
An important topic in lung cancer screening is the interval of follow-up. The 
VDTs of most benign pulmonary nodules are more than 450 days, whereas VDTs 
of malignant lesions are usually less than 400 days [29]. In several randomised 
controlled trails which are underway, the interval of early follow-up imaging is 3-, 
6-, or 12-months [30-33]. According to our screening protocol, indeterminate nod­
ules (50 - 500 mm3) had an extra repeat CT three months after the baseline ex­
amination to detect growth. Our results show that more than 75% of the resolving 
nodules disappeared at 3-month follow-up. Therefore, for indeterminate nodules 
detected in screening, a short term follow-up after initial CT could exclude a con­
siderable number of benign lesions from further work-up. 
A limitation of the current study was that the precise time point of nodule 
resolving could not be ascertained, but only the period between the first CT at 
which the nodule was detected (in this study the baseline examination) and the 
first CT after the nodule was completely disappeared. Meanwhile, histological 
evidence could not be obtained for those resolving nodules. Whether our results 
can be generalized to incidentally found nodules in a non-screening setting, still 
1 03 
Chapter 6 
needs to be proven. Further investigations should evaluate the applicability of the 
nodule management protocol as used in the NELSON study in clinical settings. 
In conclusion, about 10% of solid intraparenchymal nodules of intermediate 
size (volume, 50 - 500 mm3) found at baseline lung cancer screening disappears 
during follow-up. Our findings provide further support for a 3-month follow-up 
CT for these indeterminate lung nodules. Short-term follow-up CT is not only 
valuable to detect fast growth as determined by VDT, but also, as this study shows, 
to identify three quarters of resolving nodules. Unfortunately, resolving pulmo­
nary nodules share CT features with malignant nodules. Thus, nodule characteris­
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Summary 
Among cancers, lung cancer is the leading cause of death. Lung cancer continues 
to have a high mortality rate, despite advances in treatment. Early detection by 
imaging tests could improve the survival in lung cancer. Lung nodules are the 
predominant radiological finding of lung cancers. Computed tomography ( CT) 
has become the main imaging modality for the detection, characterization and 
follow-up of lung nodules. Quantification of pulmonary nodules by volume 
and/or diameter assessment is by now standard procedure. 
The Dutch-Belgian Randomized Lung Cancer Screening Trial (Dutch acro­
nym: NELSON) was launched in 2003. The NELSON trial focuses on nodule vol­
ume and volume-doubling time (VDT}, in contrast to other trials based on nodule 
diameter assessment. In Chapter 2, we described the details on participant re­
cruitment, CT acquisition and nodule management protocol. Valuable knowledge 
about the presence and characteristics of lung nodules on CT, and associated can­
cer risk has been obtained in the NELSON study. Small nodules ( < 50 mm3) were 
shown to have a negligible cancer risk. The results suggest that the risk of malig­
nancy in smooth or attached solid nodules with intermediate size (50 - 500 mm3) 
is also very low. In non-smooth nodules without attachment, the only predictor of 
malignancy was size. Baseline CT density of the lung nodules was found not pre­
dictive of malignancy. However, an increase in CT density was suggestive of ma­
lignancy in intermediate sized nodules. Among nodule features, size of solid nod­
ules can be considered the main factor related to cancer risk. 
A major difference between the NELSON study and other trials is the differ­
entiated manner which lung nodules were managed, according to volume, VDT 
and density (solid, part-solid, non-solid). The screening result of the solid nodule, 
the most common type of nodule, was determined by nodule volume at first de­
tection, and VDT on follow-up examinations. Management was determined based 
on the highest nodule category found. A negative screen result meant that the 
participant was invited for the regular next screening round. In case of an inde­
terminate result, a short-term repeat CT was performed to assess nodule growth. 
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A positive screen result led to referral to a pulmonologist for further work-up and 
treatment. 
In Chapter 3, we investigated the NELSON nodule management strategy 
and the results of the baseline and second round screening. A total of 7,557 par­
ticipants at high risk of lung cancer based on age and smoking behavior under­
went CT screening. The majority of screened individuals had one or more lung 
nodules. In the baseline round, 2.6% of the participants had a positive test result. 
The positive and negative predictive value was 36% and 99.9%, respectively. The 
probability of finding lung cancer one and two years after a negative baseline 
round test was very low. Nodules with a volume of 50 - 500 mm3 led to an inde­
terminate test result which required a repeat scan 3 months later to assess growth. 
In the baseline round, 92.4% of these indeterminate nodules yielded a negative 
result in the short-term follow-up CT scan. In a population at increased risk of 
lung cancer, this strategy of CT screening for lung cancer with management based 
on volume and VDT diminished the need for further work-up in participants with 
an indeterminate test result. This strategy was especially useful during the sec­
ond-round screening. It reduced the number of follow-up examinations needed in 
participants with a positive test result without reducing the overall sensitivity of 
the technique. 
In the NELSON study, CT scans were independently read by first and second 
readers. However, double reading is not widely used in clinical routine. Thus, we 
investigated the utilization of Computer-aided detection (CAD). In Chapter 4, we 
compared the performance of CAD versus double reading in randomly selected 
CT examinations from the NELSON trial. Based on a consensus panel as reference, 
the sensitivity of nodule detection was about 20% higher for CAD than for double 
reading. CAD detected nearly all lung nodules. One lung cancer was missed by 
readers, but was detected by CAD. Various factors affected nodule recognition 
during screening including reader experience and variability, CT technique and 
viewing conditions, as well as nodule characteristics. Contact with vessels in­
creased the difficulty of detection by radiologists. CAD was significantly more 
sensitive for this type of nodules. On the other hand, high false positive (FP) rate 
is a considerable drawback of CAD. Over 80% of the FPs in this study was re-
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ported only by CAD. A considerable part of FP findings for CAD concerned vessels, 
pleural plaques and rib bulging which were frequently misinterpreted due to their 
nodule-like appearance in cross-sectional images. To reduce the FP rate of CAD, 
we studied the use of a volume cut-off of 50 mm3• The use of 50 mm3 as cut-off 
volume for pulmonary nodules is supported by the NELSON results, as none of 
the interval cancers between the first and second year screening were due to ma­
lignancy in lung nodules < 50 mm3• Nearly half of the FP cases presented by CAD 
could be excluded from further evaluation if nodule size was considered, without 
missing the malignant nodules. Thus, using a combination of CAD and nodule 
size cut-off in lung cancer screening improves the sensitivity of pulmonary nodule 
detection compared to that of double reading, and significantly reduces the false 
positive rate. 
NELSON is the first large lung cancer screening trial in which semi­
automated, volumetric nodule assessment is routinely applied and forms an inte­
gral part of the nodule management protocol. Volumetric three-dimensional 
measurements have been found to be more accurate than two-dimensional 
evaluation of pulmonary nodules. In Chapter 5, we randomly selected screening 
CT examinations from the NELSON trial, to investigate different software tools 
that can be used to assess pulmonary nodules . Specifically, the software packages 
LungCARE, OncoTREAT and Vitrea were studied. The software packages yielded 
significantly different values for nodule volumes. Nodule morphology and adja­
cent structures influenced volume measurement variability. The percentage of 
satisfactory segmentations of non-smooth nodules was low for all three packages. 
Nodules adjacent to pleura and vessels showed higher volume measurement vari­
ability than well-circumscribed intraparenchymal nodules. Although no signifi­
cant difference in VDT was found between the software packages, the agreement 
in VDT categorization was only fair in this study. Thus, variations between soft­
ware results may lead to false-positive or false-negative screening conclusion. Us­
ing different software packages can influence nodule management decisions espe­
cially for intermediate-size nodules on consecutive examinations. Further stan­
dardization of software used for nodule volumetry and VDT assessment is needed 
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to optimize nodule management in lung cancer CT screening. At least different 
software tools should not be used in a single screening trial. 
In lung cancer screening, most of the intermediate-sized nodules (size 50-
500 mm3} are not malignant, and may represent granulomatous or infectious le­
sions, or enlarged lymph nodes. These benign nodules can resolve completely or 
decrease in size without intervention. The question arose whether it would be 
possible to identify specific features of nodules that will subsequently resolve, in 
order to avoid unnecessary follow-up CT. In Chapter 6, we retrospectively inves­
tigated the nodule features that predict complete disappearance of solid intrapar­
enchymal nodules detected at baseline in the NELSON trial. During subsequent 
screening rounds, 10% of indeterminate nodules disappeared. Non-peripheral and 
spiculated nodules showed a higher probability of disappearance compared to 
peripheral and smooth nodules. Thus, resolving pulmonary nodules share CT fea­
tures with malignant nodules. 
An important topic in lung cancer screening is the interval of follow-up for 
indeterminate nodules. According to our screening protocol, indeterminate nod­
ules had an extra repeat CT at three months after the baseline examination to 
evaluate growth. Our results show that by adding a 3 month follow-up CT for 
nodules of intermediate size, the number of false-positive findings could be 
greatly reduced as many intermediate nodules were found to have resolved or 
have a non-malignant growth pattern. Therefore, for indeterminate nodules de­
tected in screening, a short term follow-up after initial CT could exclude a consid­
erable number of benign lesions from further work-up. 
In conclusion, this thesis is based on data from the NELSON trial, the first 
lung cancer screening trial managing nodules using nodule volume and VDT. Our 
study confirmed that a volume-based 3D measurement is more accurate than di­
ameter-based 2D evaluation by showing an extremely low rate of interval cancers. 
Using a combination of CAD and nodule size cut-off improves the sensitivity of 
pulmonary nodule detection compared to double reading. CAD can act as a sec­
ond reader to assist radiologists in screening work and further in daily clinical 
work. Different software tools may result in deviant nodule volumetry and VDT 
assessment and thus, nodule categorization. Thus, further standardization of 
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nodule evaluation software is needed to optimize nodule management in lung 
cancer screening. For now, use of a single software package in a lung cancer 
screening study seems prudent. For indeterminate solid nodules, a short term fol­
low-up after initial CT excludes a considerable number of lesions from further 
work-up. 
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Samenvatting 
Longkanker is de voornaamste kanker-gerelateerde doodsoorzaak. Ondanks ver­
beteringen in therapie, is longkanker nog steeds geassocieerd met hoge mor­
taliteit. Vroege detectie van longkanker middels beeldvorming kan de overleving 
mogelijk doen toenemen. Longnodulen zijn de belangrijkste radiologische bevind­
ing wijzend op longkanker. Computertomografie (CT) heeft zich ontwikkeld tot 
de beeldvormende modaliteit bij uitstek voor de detectie, karakterisering en fol­
low-up van longnodulen. Kwantificatie van longnodulen door beoordeling van 
volume en/of diameter is tegenwoordig standaard. 
Het Nederlands-Leuvens Longkanker Screenings Onderzoek (acronym: 
NELSON) werd gestart in 2003. De NELSON studie richt zich op evaluatie van 
nodule volume en volume verdubbelingstijd (VDT), in tegenstelling tot andere 
trials, gebaseerd op nodule diameter meting. In Hoofdstuk 2 beschrijven we de 
details met betrekking tot de gerecruteerde deelnemers, het CT scanprotocol en 
het nodule management regime. De NELSON studie heeft al waardevolle kennis 
over het voorkomen en de kenmerken van longnodulen op CT, en geassocieerd 
kankerrisico opgeleverd. Kleine nodulen ( < 50 mm3) bleken een verwaarloosbaar 
klein kankerrisico te hebben. Resultaten wezen uit dat het risico op maligniteit in 
gladde nodulen en nodulen vastzittend aan b.v. pleura en vaten, met interme­
diaire grootte (50 - 500 mm3) ook zeer laag is. In niet-gladde nodulen in het long­
parenchym was de grootte de enige voorspeller van kanker. De densiteit van de 
longnodule op de eerste screenings CT (baseline) bleek niet voorspellend voor het 
risico op maligniteit. Aan de andere kant, toename in CT densiteit suggereerde 
wel de aanwezigheid van kanker in nodulen met intermediair volume. Van de 
nodule kenmerken kan grootte van de solide nodule worden beschouwd als de 
belangrijkste voorspellende factor voor maligniteit. 
Een groot verschil tussen de NELSON studie en andere trials op het gebied 
van CT longkanker screening, is het management protocol voor de gedetecteerde 
longnodulen. Bij de NELSON studie vond dit plaats aan de hand van volume, VDT 
en densiteit (solide, deels solide, niet solide). Het screenings resultaat van de sol­
ide nodule, het meest voorkomende type nodule, hing af van het nodule volume 
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bij de eerste detectie, en van de VDT bij vervolg screenings onderzoeken. Man­
agement regime per deelnemer werd bepaald aan de hand van de hoogste nodule 
categorie op de CT scan. Een negatieve uitslag betekende <lat de deelnemer werd 
uitgenodigd voor de gebruikelijke screening in de volgende ronde. In geval van 
een indeterminate resultaat werd op korte termijn een herhaal CT verricht om de 
groei van de longnodule te beoordelen. Een positieve uitslag leidde tot doorver­
wijzing naar de longarts voor nadere work-up en behandeling. 
In Hoofdstuk 3 werd de nodule management strategie in de NELSON studie 
onderzocht voor de baseline en tweede screeningsronde. Meer dan 7500 deelne­
mers met hoog risico op longkanker aan de hand van leeftijd en rookgedrag on­
dergingen baseline CT screening. De meerderheid van de gescreende deelnemers 
had een of meer longnodulen. In de baseline ronde had 2.6% van de deelnemers 
een positieve screeningsuitslag. De positief en negatief voorspellende waarde van 
de screenings test was 36% en 99.9%, respectievelijk. De kans op het optreden van 
longkanker een of twee jaar na een negatief baseline screeningsresultaat was zeer 
laag. Nodulen met een volume van 50 - 500 mm3 resulteerden in een indetermi­
nate testresultaat en een herhaal CT screening na 3 maanden om groei te evalu­
eren. In de eerste screenings ronde leverde deze korte termijn herhaal screening 
in meer dan 90% van deelnemers met een indeterminate nodule een negatief re­
sultaat op. In een populatie met verhoogd risico op longkanker verminderde de 
NELSON strategie de noodzaak voor nadere diagnostiek in deelnemers met een 
indeterminate screenings resultaat. Deze strategie was in het bijzonder effectief 
tijdens de tweede screenings ronde. De nodule management strategie op basis van 
volume en VDT reduceerde het aantal benodigde vervolg onderzoeken in deelne­
mers met een positief testresultaat, zonder de gevoeligheid van de techniek voor 
detectie van longkanker omlaag te brengen. 
In de NELSON studie werden CT scans onafhankelijk door twee beoordelaars 
bekeken. Echter in de klinische praktijk komt deze dubbele evaluatie (double 
reading) niet vaak voor. Daarom werd de inzet van computer-ondersteunde de­
tectie ('Computer-Aided Detection', CAD) onderzocht. In Hoofdstuk 4 vergele­
ken we de accuratesse van CAD ten opzichte van dubbele evaluatie, gebruikma­
kend van een steekproef uit de NELSON studie. De gevoeligheid voor nodule de-
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tectie was ongeveer 20% hoger voor CAD dan voor dubbele evaluatie, met het 
oordeel van een consensus panel als referentie. CAD vond bijna alle longnodulen. 
Een geval van longkanker werd door menselijke beoordelaars gemist, maar wel 
gevonden met behulp van CAD. Factoren die het herkennen van longnodulen 
bei:nvloedden waren onder andere ervaring van de beoordelaars, CT techniek en 
omgeving waarin beoordeeld werd, alsmede nodule kenmerken. Radiologen had­
den meer moeite om nodulen te detecteren als deze vast zaten aan vaten. CAD 
was gevoeliger voor detectie van dit soort nodulen. Aan de andere kant, gebruik 
van CAD leverde veel meer fout positieve bevindingen op, structuren die geen 
longnodulen bleken te betreffen. Meer dan 80% van de fout positieve bevindingen 
werden alleen door CAD gedetecteerd. Een belangrijk deel van de fout positieve 
bevindingen betroffen vaten, pleurale verdikkingen en rib uitsteeksels, die door 
CAD verkeerd waren gei:nterpreteerd als longnodulen. Om het percentage fout 
positieve bevindingen voor CAD te verminderen, werd een afkapwaarde voor het 
volume van te detecteren nodule onderzocht. Hiervoor werd een volume van 
tenminste 50 mm3 gebruikt. Deze volume afkapwaarde wordt ondersteund door 
resultaten in de NELSON studie, aangezien longnodulen < 50 mm3 niet leidden 
tot intervalkankers tussen de eerste en tweede screeningsronde. Bijna de helft van 
alle fout positieve bevindingen voor CAD konden warden geexcludeerd als de 
nodule grootte werd betrokken in de beoordeling, zonder dat maligne nodulen 
gemist werden. Het gebruik van een combinatie van CAD en nodule grootte 
afkapwaarde in longkanker screening verbetert de gevoeligheid van longnodule 
detectie vergeleken met dubbele evaluatie, en vermindert het aantal fout positieve 
bevindingen. 
NELSON is de eerste longkanker screening trial waarin semi-automatische 
berekening van nodule volume routinematig wordt toegepast, en integraal deel 
uitmaakt van het nodule management protocol. Drie-dimensionale, volume met­
ingen zijn accurater gebleken dan twee-dimensionale, diameter evaluatie van 
longnodulen. In Hoofdstuk 5 werden verschillende software pakketten voor met­
ing van longnodule grootte gebruikt om een steekproef van screenings CT onder­
zoeken te beoordelen. Het ging specifiek om LungCARE, OncoTREAT and Vitrea. 
De waarden voor nodule volume die voor de verschillende software pakketten 
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werden gevonden, weken van elkaar af. Morfologie van nodulen en aangrenzende 
structuren be'invloedden de variabiliteit in volume meting. Het percentage ade­
quate segmentatie van niet-gladde nodule was laag voor alledrie de software pak­
ketten. De variabiliteit in volumetrie was hoger voor nodulen aangrenzend aan 
pleura en vaten, dan voor scherp afgrensbare nodulen in het longparenchym. Al­
hoewel er geen significant verschil in VDT gevonden werd tussen de software 
pakketten, was de overeenkomst in categorisatie van nodulen op basis van VDT 
slechts matig. Variatie in software metingen kunnen leiden tot fout positieve of 
fout negatieve screenings resultaten. Het gebruik van verschillende software pak­
ketten kan beslissingen over de management van longnodulen verschillend doen 
uitvallen, vooral in geval van vervolg CT onderzoeken voor nodulen met interme­
diair volume. Verdere standardisatie van software voor nodule volume en VDT 
bepaling is nodig om de nodule management strategie in longkanker CT screen­
ing te optimaliseren. Ten minste zou in een longkanker screening studie gebruik 
gemaakt moeten worden van een en hetzelfde software pakket. 
De meeste longnodulen met intermediaire grootte (50 - 500 mm3) die 
worden gevonden op CT screenings onderzoeken, zijn geen kanker. Deze nodulen 
kunnen b.v. granulomateuze of infectieuze lesies betreffen, of vergrote 
lymfklieren. Deze goedaardige nodulen kunnen verdwijnen of kleiner worden 
zonder enige behandeling. De vraag kwam op of bepaalde nodule kenmerken erop 
wijzen <lat de nodule op vervolg onderzoeken verdwenen is, met als doe! om on­
nodige herhaal CT scans te voorkomen. In Hoofdstuk 6 werd retrospectief on­
derzocht welke nodule kenmerken het verdwijnen van een solide, in het longpar­
enchym gelegen nodule voorspelt. Hiervoor werden nodulen geevalueerd die 
waren ontdekt bij de baseline screenings ronde. Bij volgende screenings ronden 
bleek 10% van de indeterminate nodulen verdwenen. Niet-perifere nodulen en 
gespiculeerde nodulen verdwenen vaker dan perifere en gladde nodulen. Derhalve 
overlappen de kenmerken van nodulen die verdwijnen, met de kenmerken van 
maligne nodulen. 
Een belangrijk onderwerp in longkanker screening is het interval voor opvol­
gen van indeterminate nodulen. Volgens het NELSON protocol voor de baseline 
ronde werd dan een extra herhaal CT verricht na 3 maanden, om nodule groei te 
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beoordelen. Onze resultaten tonen aan <lat door deze korte termijn herhaal CT 
scan voor indeterminate nodule, het aantal fout positieve bevindingen in long­
kanker screening naar beneden gebracht kan worden. Op het herhaal CT onder­
zoek bleken veel nodulen met initieel intermediaire grootte namelijk verdwenen 
of een niet-maligne groeipatroon te hebben. Daarom kan een korte termijn her­
haal CT onderzoek nadere diagnostiek voor veel deelnemers met indeterminate 
screenings resultaat voorkomen. 
Concluderend beschrijft dit proefschrift resultaten van de NELSON studie, 
het eerste longkanker screenings onderzoek waarin longnodule management ge­
baseerd is op nodule volume en VDT. Onze studie bevestigt dat nodule volume 
bepaling accurater is dan diameter meting, gezien het lage percentage interval­
kankers tussen de screenings ronden. Een combinatie van CAD en volume afkap­
waarde verbetert de gevoeligheid voor nodule detectie vergeleken met dubbele 
evaluatie. CAD kan als een tweede beoordelaar fungeren, om radiologen te assis­
teren in het screeningswerk en in de klinische praktijk. Verschillende software 
pakketten kunnen leiden tot verschillen in nodule volumetrie en VDT bepaling, 
en dus, tot verschillen in nodule categorizatie en management. Verdere stan­
dardisatie van nodule evaluatie software is nodig om het nodule management re­
gime in longkanker screening te optimaliseren. Het is aan te bevelen in een long­
kanker screening studie gebruik te maken van een software pakket. Een korte 
termijn herhaal CT onderzoek na de eerste screening kan een aanzienlijk deel van 
indeterminate, solide longnodulen identificeren die geen nadere diagnostiek be­
hoeven. 
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